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Resumo 
 
 Devido a importância de complexos metálicos na medicina, como cisplatina (e seus 
derivados), sulfadiazina de prata e auranofina, novos compostos de coordenação tem sido 
estudados como potenciais candidatos a fármacos para aplicação na clínica médica. 
O desenvolvimento de um câncer pode estar intimamente ligado a processos 
inflamatórios. Existem estudos que sugerem que a ingestão regular de ibuprofeno e outros 
anti-inflamatórios não esteroidais protege contra o surgimento e crescimento de diversos 
tipos de câncer. Além disso, muitas moléculas que contém a função hidrazida tem mostrado 
um amplo espectro farmacológico, incluindo atividades antimicrobianas e antitumorais. 
Hidrazidas também são capazes de interagir com proteínas carreadoras que melhoram o 
perfil toxicológico e a seletividade frente a células tumorais.  
Complexos de paládio(II) e platina(II) com uma hidrazida derivada do ibuprofeno (HIB) 
foram sintetizados e caracterizados por um conjunto de análises químicas e 
espectroscópicas. Os resultados das análises elementar e térmica, bem como dos estudos 
por espectrometria de massas (ESI-QTOF-MS), confirmaram as composições na razão 1:2:2 
metal/HIB/cloreto. A estrutura cristalina do complexo de paládio(II) foi determinada por 
difratometria de raios X de monocristal. Este complexo apresenta a fórmula mínima 
[PdCl2(HIB)2] com o ligante HIB coordenado ao íon metálico pelo grupo amina. Cálculos por 
DFT (Density Functional Theory) foram aplicados para que fosse possível sugerir a estrutura 
do complexo de Pt(II). As análises por ressonância magnética nuclear e espectroscopia no 
infravermelho reforçam que a coordenação observada na estrutura cristalina e calculada por 
DFT estão corretas. Ensaios de atividade antiproliferativa frente a células tumorais e não-
tumorais e ensaios de inibição bacteriana foram realizados para avaliar a atividade biológica 
dos complexos obtidos. O complexo de Pd(II) mostrou-se ativo para a linhagem de câncer 
de ovário OVCAR-03 com boa seletividade. O complexo de Pt(II) não se mostrou ativo. 
Nenhum dos complexos foi ativo sobre as cepas bacterianas testadas. Também foram 
aplicadas técnicas de fluorescência e dicroísmo circular para avaliar a interação dos 
compostos com DNA, sendo que o complexo de Pd(II) foi o único capaz de interagir com 
DNA. Estes resultados sugerem que o DNA é um alvo biológico para o complexo de Pd(II). 
  
 
 
 
 
Abstract  
 
Given the importance of metal-based drugs such as cisplatin (and their derivatives), 
silver sulfadiazine and auranofin, novel metal complexes have been studied as promising 
drug candidates and are attracting attention in modern clinical medicine. 
Cancer developing can be closely related to inflammatory processes. There are studies 
suggesting that the regular intake of ibuprofen and other non-steroidal anti-inflammatory 
drugs protect against the development of several types of cancer. Also, many molecules 
containing the hydrazide moiety have shown to have broad pharmacological activities, 
including antimicrobial and antitumor ones. These kind of compounds are known to interact 
with carrier proteins to improve their antitumor selectivity and toxicity profile and can also act 
as DNA modifying agents. 
Palladium(II) and platinum(II) complexes with a hydrazide derivative of ibuprofen (HIB), 
were synthesized and characterized chemically and spectroscopically Elemental and 
TGA/DTA analyses as well as ESI-QTOF-MS analysis for both complexes confirmed a 1:2:2 
metal/HIB/Cl- ratio. The crystal structure of the palladium(II) complex was obtained and 
refined by single-crystal X-ray diffractometry, presenting a minimal formula of [PdCl2(HIB)2] 
with HIB coordinating to the metal ion by the amine moiety. Density Functional Theory (DFT) 
calculations were also performed to propose the structure of the Pt(II) complex. Nuclear 
magnetic resonance and infrared spectroscopies reinforces the coordination observed in the 
crystal structure and DFT calculations. Antiproliferative and antibacterial assays in vitro were 
performed to evaluate the activity of the complexes obtained. The Pd(II) complex was active 
in vitro against the OVCAR-03 ovarian cancer cell line, with good selectivity. The Pt(II) 
complex showed no biological activity. Fluorescence and circular dichroism spectroscopic 
techniques were used to evaluate the interaction of the compounds with DNA. Only the Pd(II) 
complex was able to interact with this biomolecule, which suggests that DNA is a target for 
this compound. 
  
 
 
 
 
 
Figures list  
Pag. 14 - Figure 1. Platinum based drugs currently used in medicinal clinic. 
Pag. 17 - Figure 2. Ibuprofen (R = OH) and ibuprofen hydrazide (R = NHNH2) molecular 
structures. 
Pag. 26 - Figure 3. (A) View of asymmetric part of unit cell of the complex PdHIB. (B) 
Representation of the hydrogen bonds observed among the moieties [symmetry codes:(i) 1-
x,-y,1-z, (ii) x, 1/2-y, -1/2+z, (iii) 1-x, 1-y, 1-z]. For clarity, the disorder on the isopropyl group 
was intentionally not represented. Probability level of ellipsoids: 50%. 
Pag. 27 - Figure 4. Representation of the unit cell of PdHIB. 
Pag. 28 - Figure 5. Infrared spectra of HIB (A), PdHIB (B) and PtHIB (C). 
Pag. 29 - Figure 6. TG (blue) and DTA (black) curves for PdHIB (A) and PtHIB (B) 
Pag. 30 - Figure 7. UV spectra of HIB, PdHIB and PtHIB in methanol. 
Pag. 31 - Figure 8. UV-Vis spectra of PdHIB in DMSO (A), PdHIB in MeOH (B), PtHIB in 
DMSO (C) and PtHIB in MeOH (D) in the time range from 0 to 22 hours. 
Pag. 32 - Figure 9. 1H NMR spectrum of HIB in DMSO-d6. On top of the peaks are shown 
the chemical shifts and at the bottom are the integrated intensities. An expansion from 1.7 to 
3.5 ppm is presented on the top left corner. 
Pag. 32 - Figure 10. {15N,1H} HSQC NMR spectrum of HIB in DMSO. The chemical shifts of 
the nitrogen atoms are shown.    
Pag. 33 - Figure 11. 1H NMR spectrum of HIB in MeOD. On top of the peaks are shown the 
chemical shifts and in the bottom are the calculated integrals. An expansion from 1.6 to 2.1 
ppm highlights the signal of the hydrogen H10. 
Pag. 34 - Figure 12. NMR spectrum of HIB {13C,1H} HSQC in MeOD. 
Pag. 34 - Figure 13. NMR spectrum of HIB {13C,1H} HMBC in MeOD. 
Pag. 35 - Figure 14. NMR spectrum of PdHIB {13C,1H} HMBC in DMSO-d6. 
Pag. 36 - Figure 15. NMR spectrum of PtHIB {13C,1H} HMBC in MeOD. 
Pag. 38 - Figure 16. 15N SSNMR spectra of HIB (A), PdHIB (B) and PtHIB (C). 
Pag. 39 - Figure 17. (A) Mass spectra for the PdHIB complex from 100 to 1000 m/z. (B) 
Theoretical isotope pattern for the complex [Pd(HIB)2Cl]+. (C) ESI(+)-QTOF mass spectrum 
of PdHIB from 576 to 590 m/z. The notation HIB refers to C13H20N2O. 
 
 
 
 
Pag. 39 - Figure 18. (A) Mass spectra for the PtHIB complex from 100 to 1000 m/z. (B) 
Theoretical isotope pattern for the complex [Pt(HIB)2Cl]+. (C) ESI(+)-QTOF mass spectrum 
of PtHIB from 668 to 680 m/z. The notation HIB refers to C13H20N2O. 
Pag. 40 - Figure 19. PBE0/def2-TZVP optimized structure of [PtCl2(HIB)2]. 
Pag. 41 - Figure 20. PBE0/def2-TZVP optimized structure of [PdCl2(HIB)2]. 
Pag. 42 - Figure 21. Comparison between the crystal structure of [PdCl2(HIB)2] and its 
optimized structure by DFT. The structures were overlapped considering the common 
positions of the metal ion and its first coordination sphere. The crystal structure is represented 
as ellipsoids and the DFT structure is represented as sticks. The hydrogen atoms were 
intentionally omitted. 
Pag. 47 - Figure 22. Molecular structure of SYBR Green. 
Pag. 48 - Figure 23. Relative fluorescence intensities of SG at 250 nm for samples of free 
DNA and DNA in the presence of PdHIB in the ratios (compound/DNA) 0.1, 0.2, 0.3. 
Pag. 49 - Figure 24. CD spectra of CT-DNA in absence and presence of PdHIB in the ratios 
(complex/ DNA) of 0.1, 0.2 and 0.3. The vertical bars represent the experimental error 
between three measurements. 
 
 
 
  
 
 
 
 
Tables list  
Pag. 25 - Table 1. Crystallography data for PdHIB. 
Pag. 37 - Table 2. Chemical shifts in the 13C and 15N SSNMR for HIB, PdHIB and PtHIB.  
Pag. 43 - Table 3. Selected bond lengths for the Pd(II) and Pt(II) complexes in comparison 
to the literature and to the crystal structure of [PdCl2(HIB)2]. The bond lengths calculated by 
DFT are presented in average. 
Pag. 45 - Table 4. GI50 (μmol·L-1) and selectivity index (SI) values obtained for HIB, 
[PdCl2(HIB)2], [PtCl2(HIB)2], K2[PdCl4], K2[PtCl4] and doxorubicin in the in vitro 
antiproliferative assay. 
 
  
 
 
 
 
Abbreviations list 
CD…………………………........... Circular dichroism spectroscopy 
CFU……………………………….. Colony-forming unit 
CSD……………………..………… Cambridge Structural Database 
CT-DNA…………………….…….. Calf thymus - Deoxyribonucleic acid 
DFT…………………………….…. Density Functional Theory 
DMSO…………………………….. Dimethyl sulfoxide 
ESI-QTOF-MS............................. Electrospray ionization time of flight mass spectrometry 
HIB………………….…………….. Ibuprofen hydrazide  
HMBC…………………….………. Heteronuclear multiple bond coherence 
HSQC……………………..………. Heteronuclear single quantum coherence 
ibu…………………………..…...... Ibuprofen 
IR………………………………...... Infrared spectroscopy 
MeOD……………………………... Methanol-d3 
MIC………………………..………. Minimal inhibitory concentration 
NMR………………………….…… Nuclear magnetic resonance 
HaCat ……................................. Immortal keratinocyte (non-tumor human cell line).  
NSAIDs………………………....... Non-steroidal anti-inflammatory drugs 
[PdCl2(HIB)2] or PdHIB………..... Pd(II) complex with ibuprofen hydrazide 
[PtCl2(HIB)2] or PtHIB…………… Pt(II) complex with ibuprofen hydrazide 
SSNMR....………………………… Solid state nuclear magnetic resonance 
SYBR Green or SG……………… Nucleic acid electrophoresis stain SYBR® Green I: N',N'-
dimethyl-N-[4-[(E)-(3-methyl-1,3-benzothiazol-2-
ylidene)methyl]-1-phenylquinolin-1-ium-2-yl]-N-
propylpropane-1,3-diamine 
TG/DTA……………………….….. Thermogravimetric and differential thermal analysis 
Tumor human cell lines…………. U251 (glioma); UACC-62 (melanoma); MCF-7 (breast); 
NCI-ADR/RES (multidrug resistant ovarian); NCI-H460 
(lung, non-small cells); PC-3 (prostate); OVCAR-03 
(ovarian); HT-29 (colon); K562 (leukemia). 
  
 
 
 
 
Summary 
________________________________________________________________________________________ 
1. Introduction ............................................................................................................................................ 13 
1.1 The role of metal based drugs on cancer treatment ................................................................. 13 
1.2 Ibuprofen: biological activities and applications in medicine .................................................... 15 
1.3 Hydrazides ....................................................................................................................................... 16 
2. Objectives ............................................................................................................................................... 18 
2.1. General aims and scope ................................................................................................................ 18 
2.2. Specific objectives .......................................................................................................................... 18 
3. Experimental section ........................................................................................................................... 19 
3.1. Materials and Methods ................................................................................................................... 19 
3.2. Geometry optimizations ................................................................................................................. 20 
3.3. Antibacterial assays in vitro ........................................................................................................... 20 
3.4. Antiproliferative assays in vitro. .................................................................................................... 21 
3.5. Biophysical studies of interaction with DNA ............................................................................... 22 
3.6. Synthesis .......................................................................................................................................... 22 
3.6.1. Ibuprofen hydrazide (HIB). .................................................................................................... 22 
3.6.2. PdHIB complex ........................................................................................................................ 23 
3.6.3. PtHIB complex. ........................................................................................................................ 23 
4. Results and discussion ...................................................................................................................... 24 
4.1 Single crystal X-ray diffraction ...................................................................................................... 24 
4.2 Infrared spectroscopy ..................................................................................................................... 27 
4.3 Thermogravimetric and differential thermal analyses (TG/DTA) ............................................. 28 
4.4 Stability in solution .......................................................................................................................... 29 
4.5 NMR spectroscopy ......................................................................................................................... 31 
4.6 Mass spectrometric measurements ............................................................................................. 38 
4.7 DFT calculations ............................................................................................................................. 40 
4.8 Biological assays ............................................................................................................................ 44 
4.8.1 Minimal inhibitory concentration (MIC) ................................................................................ 44 
4.8.2 Antiproliferative assays .......................................................................................................... 44 
4.9 Biophysical studies: interaction with DNA ................................................................................... 46 
4.9.1 Fluorescence studies with SYBR Green (SG).................................................................... 47 
4.9.2 Circular dichroism spectroscopy ........................................................................................... 48 
5. Conclusions ........................................................................................................................................... 50 
6. Bibliographic references .................................................................................................................... 52 
7. Appendix ................................................................................................................................................. 58 
13 
 
 
1. Introduction 
 
1.1 The role of metal based drugs on cancer treatment 
 
Cancer is one of the most significant public health case of concern in the world. 
According to the latest cancer report by the World Health Organization (WHO), cancer was 
responsible for 8.8 million deaths in 2015, which corresponds to nearly 1 in 6 deaths 
worldwide ["Cancer Fact sheet " World Health Organization, February 2017. Retrieved 24 
August 2017].  
 Cancer can be defined as a collection of diseases related with abnormal and 
uncontrollable cell replication that may occur in any tissue. More specifically, cancer cells 
have self-sufficiency in growth signals and are insensitive to anti-growth signals, being 
capable to avoid mechanisms of apoptosis (programmable cell death), therefore they have 
unlimited replicative potential. Another important characteristic of cancer is the capacity to 
spread and invade different tissues, known as metastasis. This process is facilitated by 
sustained angiogenesis in the cancerous tissues1. 
Even though a great effort has been made over the past decades to treat cancer more 
effectively and safely, the pace of drug development is far behind the increasing rate of 
cancer incidence and mortality2,3, mainly due to cancer heterogeneity and acquired 
resistance to conventional chemotherapeutic drugs4. Prospects by the U.S. National Cancer 
Institute show that the number of cancer cases will rise 50% and cancer deaths are projected 
to increase by 60% until 2030 ["The Burden of Cancer Worldwide" National Cancer Institute, 
Retrieved 24 August 2017] 
The new era of metal-based drugs started in 1960´s when Barnett Rosenberg et al. 
showed the cisplatin capacity to inhibit cellular division in Escherichia coli 5. This discovery 
lead to further studies in eukaryotic cells about its antitumor activity, and cisplatin became 
one of the most used and potent drugs against different types of cancer, such as lung, head 
and neck, testis and ovarian cancers. Nowadays, novel metal-based drugs are attracting 
attention in modern clinical medicine6,7. 
It is estimated that platinum drugs are used in 50% of all cancer chemotherapy8, 
showing great results especially for testicular and ovarian cancer. However, limitations of 
their uses remain as a challenge to the scientific community. The increasing cisplatin cross-
resistance developed by tumors, the narrow spectrum of antitumor activity, high toxicity and 
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challenging delivery are examples of these limitations9,10. In this context, in order to overcome 
the resistance in tumors, high systemic doses of the platinum-based drugs are necessary to 
achieve an effective intracellular concentration resulting in severe systemic toxicity11.  
Many derivatives of cisplatin were developed hoping to overcome part of such 
limitations. Figure 1 shows the platinum based drugs approved for use in medicine12, in which 
cisplatin, carboplatin and oxaliplatin are approved worldwide, while nedaplatin, nobaplatin 
and heptaplatin are only approved to be used in Japan, China and Korea, respectively.  
 
 
Figure 1. Platinum based drugs currently used in medical clinic. 
 
The similarities between these drugs are promptly observed. All of them are Pt(II) 
complexes, with square geometries and ligands in a cis configuration. Pt(II) complexes act 
as prodrugs, requiring replacement of their labile ligands with water before they are able to 
bind and disrupt DNA function.12 Generally, the toxicity of these drugs is directly related to 
the rate of exchange of the leaving groups for water molecules. For instance, cisplatin has 
two very labile chloride ligands that are easily substituted by water molecules in biological 
environments. Therefore it is significantly more toxic than the other Pt-based drugs that have 
bis-carboxylate ligands designed to increase the drug stability13,14. Other improvement made 
over the cisplatin structure is the addition of diamine bulky ligands ((1R,2R)-cyclohexane-1,2-
diamine in the case of oxaliplatin) to overcome cisplatin cross-resistance by preventing 
binding of DNA repair proteins to Pt-DNA adducts15. 
Not only cis-Pt(II) drugs are known to have antitumor activity. Many trans-Pt(II) 
complexes were reported to be as active as cisplatin in various assays. Some of them have 
shown to be effective against cisplatin resistant cancer cells with slightly different 
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mechanisms.16 Also, polynuclear platinum anti-cancer agents that have unique mechanisms 
of action were extensively studied by Farrell et. al. 17–19 and have great potential as new 
antitumor drugs. 
Considering the successful application of platinum(II) complexes in cancer therapy and 
the similarity between platinum(II) and palladium(II) compounds, the latter metal was also 
considered in the synthesis of promising anticancer drugs, with good anticancer and 
antimicrobial in vitro and in vivo activities.20 In general, Pd(II) coordination compounds have 
faster ligand exchange kinetics than their Pt(II) analogs, which usually causes rapid 
hydrolysis in biological medium, leading to higher toxicity and less systemic distribution.21 For 
these reasons, its usually necessary to choose chelating ligands that stabilize the Pd(II) 
complexes, so that they reach the pharmacologic target. Palladium(II) complex are also 
usually more soluble than the correspondent Pt(II) complexes. 7,21 
There are different strategies that can be applied in the synthesis of new metal-based 
drugs for treatment of diseases as cancer. One of them is to align the cytotoxic properties of 
a metal ion with the desired activity of a specific ligand. An interesting approach is to use a 
particularly non-anticancer drug as ligand with favorable safety profile, known 
pharmacokinetics, coordination ability in the viewpoint of coordination chemistry and 
adequate permeability 2. This approach was applied in the present work by choosing as ligand 
a derivative of ibuprofen in the synthesis of platinum(II) and palladium(II) complexes aiming 
the obtainment of new anticancer agents. 
 
1.2 Ibuprofen: biological activities and applications in medicine 
 
Ibuprofen is one of the most used non-steroidal anti-inflammatory drug (NSAID) in the 
medical clinic. It is used for the treatment of headache, muscular ache, arthritis rheumatoid, 
fever and pain related to tissue inflammation. Concerning cancer therapy, there are studies 
suggesting that the regular intake of ibuprofen and other NSAIDs protects against the 
development of many types of cancer including colon, breast, lung, and prostate cancer 22–
24. Cancer risk reductions are apparent after five or more years of regular anti-inflammatory 
use, with ibuprofen being the NSAID that produced the greater risk reductions (72% for colon 
cancer, 52% for breast cancer, 52% for lung cancer and 53% for prostate cancer)22. 
 For ibuprofen, this property might be related to the chiral inversion pathway that 
converts the R-ibuprofen to its more effective anti-inflammatory enantiomer S-ibuprofen by 
the enzyme -methylacyl-CoA racemase (AMACR). The organism processing of ibuprofen 
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reduces the normal activity of AMACR, which could reduce cancer developing. Although this 
mechanism study is still not conclusive, it is an interesting subject of study because AMACR 
is used as a marker (P504S) for several types of cancers25,26.  
Even though the role of ibuprofen appears to be in cancer prophylaxis rather than 
treatment, its interaction with a marker for cancer (AMACR – P504S)27,28 by itself could be 
explored, using ibuprofen as an organic directing molecule and taking advantage of its 
pharmacological properties.  
Concerning treatment and prevention of post-surgical infections, NSAIDs are commonly 
used concomitantly to antibiotics to reduce the level of tissue inflammation29. Therefore, anti-
inflammatory ligands are particularly interesting for association with metal ions in the design 
and development of new pharmacological agents. 
Given the relevance of ibuprofen, there are many examples of metal complexes with 
ibuprofen bearing antibacterial activity, such as silver(I) and gold(I) ibuprofen complexes30,31 
which are active against Gram-positive and Gram-negative strains and Pt(II) ibuprofen 
complex [Pt(1,2-diaminciclohexane)(ibuprofen)2], which is active against Gram-positive 
microorganisms32. There is also a patent describing the use of Cu(II) and Zn(II) complexes 
with ibuprofen33,34 as prophylaxis agents against cardiovascular inflammation and for 
prophylaxis and treatment of diabetes30. It is interesting to notice that none of these 
complexes were evaluated as antitumor agents, although complexes Au(I), Pt(II) and Cu(II) 
are usually evaluated as potential anticancer drugs35. 
Many derivatives of ibuprofen have been studied as well. Derivatives with s-triazines and 
1,3-diaryl pyrazole, showed, respectively, higher analgesic and anti-inflammatory activities 
than free ibuprofen36,37. Moreover, ibuprofen conjugated with oligo(3-hydroxybutyrate) were 
able to inhibit in vitro proliferation of colon cancer cells (HT-29 and HCT 116)38.  
 
1.3 Hydrazides  
 
 Hydrazides and their derivatives are shown to have a broad pharmacological activities, 
including the antimicrobial and antitumor ones. For hydrazides and hydrazones of NSAIDs, 
the modification of the acidic site of these molecules are desired to partly reduce the adverse 
effects to the gastrointestinal tract39,40. 
There are several examples of biological active hydrazides41. Some of them are 
isonicotinohydrazide as an antituberculosis drug42, N'-isopropylisonicotinohydrazide with 
antidepressant activity43 and sulfonyl hydrazide derivatives that not only exhibit a wide range 
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of bacteriostatic activity, but also can act as DNA modifying agents. They have exhibited 
antitumor activities against murine tumors, including the B16 melanoma, M109 lung 
carcinoma, L1210 leukemia, P388 and M5076 reticulum cell sarcoma44. 
Regarding coordination chemistry, the derivatization of ibuprofen to a hydrazide adds 
two nitrogen atoms to the structure (see Figure 2) and introduces a new coordination site by 
the NH2 group, in detriment of an acidic COOH coordination site. According to Pearson’s acid 
base theory, stronger coordination bonds are formed by a pair of soft acid with soft base or 
hard acid with hard base45. Although classified as a hard base, nitrogen can be considered a 
softer Pearsons’ bases than oxygen, being able to form more stable complexes with soft 
acids such as Pt(II) and Pd(II). As earlier discussed, the stability of Pt(II) and Pd(II) 
complexes, especially in biological environments, is desirable in most cases. 
So, in this work we present the synthesis and characterization of new Pd(II) and Pt(II) 
complexes with a hydrazide derived from the NSAID ibuprofen (Figure 2) and the studies of 
the antiproliferative profile of the compounds over a panel of tumor cells and their activities 
over bacterial strains. Studies about interaction of the compounds with calf thymus DNA (CT-
DNA) by circular dichroism and fluorescence spectroscopy were also performed to provide 
preliminary information about the mechanism of action of the complexes. 
 
 
Figure 2. Ibuprofen (R = OH) and ibuprofen hydrazide (R = NHNH2) molecular 
structures. 
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2. Objectives 
 
2.1. General aims and scope  
The aim of this work was synthesize an hydrazide of ibuprofen and its new metal 
complexes of Pt(II) and Pd(II), and evaluate their antitumor and antibacterial activities. 
 
2.2. Specific objectives 
 
• Optimize the synthesis of the ligand (ibuprofen hydrazide) and of the Pt(II) and Pd(II) 
complexes. 
• Characterize the ligand and the corresponding complexes using chemical and 
spectroscopic techniques to determine their composition and structures. 
• Use density functional theory (DFT) calculations to propose structures correlating with 
the experimental data. 
• Evaluate the in vitro biological activity of the compounds against bacteria and cancer 
cells. Compare the activities observed for ligand and complexes. 
• Study the interaction of the compounds with DNA and correlate the results with the 
biological activities. 
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3. Experimental section 
 
3.1. Materials and Methods 
 
Ibuprofen (racemic) was obtained from Maxpharm Industries. DNA sodium salt from 
calf-thymus type I, SYBR Green I 10,000x in DMSO and K2PtCl4 were purchased from 
Sigma–Aldrich Laboratories. K2PdCl4 and hydrazine hydrate (64%) were purchased from 
Acros Laboratories. Methyl chloroformate (99%), dichloromethane (99%) and triethylamine 
(99%) were purchased from Spectrum Chemical Mfg, LabSynth and Merck Laboratories, 
respectively. Triethylamine was purified by distillation with potassium carbonate while 
dichloromethane was purified by distillation with phosphorous pentoxide (P2O5) prior to the 
syntheses. Methyl chloroformate were also purified by distillation prior to the syntheses. 
Elemental analyses were performed on a Perkin Elmer 2400 CHNS/O Analyzer. 
Electronic spectra in the 190–1100 nm range were acquired by using a 1.0 cm quartz cuvette 
in a diode array HP8453 UV/Vis absorption spectrophotometer. Infrared spectroscopy 
measurements were performed on an Agilent Cary 630 FTIR spectrometer, using the 
Attenuated Total Reflectance (ATR) method, with a diamond cell. Spectra were recorded 
from 400-4000 cm-1, with 64 scans and resolution of 4 cm-1.  
The 1H and 13C NMR spectra of HIB, PdHIB and PtHIB were recorded in a Bruker 
Avance III 500 MHz (11.7 T) spectrometer. The {15N,1H} and {13C,1H} correlation NMR spectra 
were recorded in a Bruker Avance III 400 MHz (9.4 T) spectrometer. Samples were analyzed 
at 298 K. PdHIB was analyzed in a DMSO-d6 solution, while PtHIB was analyzed in methanol-
d3 due to its better stability in this solvent. HIB was analyzed in both methanol-d3 and DMSO-
d6. The chemical shifts for all solution measurements were given relative to tetramethylsilane 
(TMS). All the 13C and 15N solid state NMR (SSNMR) spectra were recorded in a Bruker 300 
MHz spectrometer, using the combination of cross-polarization, proton decoupling and magic 
angle spinning techniques (CP/MAS) at 10 kHz.  
Electrospray ionization mass spectrometry (ESI-MS) measurements were carried out 
using a Waters Quattro Micro API. Samples were evaluated in the positive mode. Each 
solution was directly infused into the instrument’s ESI source and analyzed in the positive 
mode, with capillary potential of 3.00 kV, trap potential of 2 kV, source temperature of 150°C 
and nitrogen gas for desolvation.  
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3.2.  Geometry optimizations 
 
The theoretical calculations of the complexes were carried out using density functional 
theory (DFT) with a PBE0 hybrid functional 46 and the def2-TZVP basis set 47 for all atoms 
using ORCA software 48. The geometric optimization was performed with a convergence 
criterion of 10-5 a.u. for the gradient and 10-8 a.u. for the density. The RIJCOSX method 49 
was used for the calculation of the exchange energy, using the standard number of points for 
the grid calculations. The structures were confirmed as the minimum of the potential energy 
surface (PES) using the same level of theory. Illustrations were rendered using the Pov-Ray 
tool on Mercury CSD 3.8 (Copyright CCDC 2001-2016) 
[http://www.ccdc.cam.ac.uk/mercury/]. 
 
3.3. Antibacterial assays in vitro 
 
Antimicrobial assays were performed in collaboration with Prof. Dr. Wilton Rogério 
Lustri from the Biological and Health Sciences Department, University of Araraquara 
(UNIARA). In this study, Gram-positive Staphylococcus aureus (ATCC 25923), and Gram-
negatives Escherichia coli (ATCC – 25922) and Pseudomonas aeruginosa  (ATCC-27853) 
bacterial strains were inoculated in tubes containing BHI (Brain Heart Infusion KASVI) and 
incubated for 18 hours at 35-37 °C. Appropriate amounts of each bacterial suspension were 
added to new tubes in BHI sterile culture medium until the 1.0 nephelometric McFarland 
turbidity scale (~3.0x108 CFU/mL). Volumes of 50 µL of the samples HIB, PdHIB and PtHIB 
suspended in DMSO (15 µg·µL-1) were added to the second well of the 96 well microplate, 
followed by the addition of 50 µL of BHI sterile. In the next 6 wells a serial dilution (half) in 
BHI sterile was performed, maintaining the final volume of 100 µL per well. After that, 100 µL 
of the bacteria suspensions were added to each serial dilution reaching 0.5 in the McFarland 
turbidity scale (~1.5x108 CFU/mL) and the concentrations of the compounds between 3750 
µg·mL-1 and 58.6 µg·mL-1 for a final volume of 200 µL per well. The first well of the plate was 
used as control for bacterial growth, containing only the bacteria suspension (~1.5x108 
CFU/mL). The microplates were incubated for 18 h at 35-37 °C in a wet chamber under 
stirring at 100 rpm. After the incubation time, 15 μL of resazurin 0.02% in sterile aqueous 
solution were added. The measurements were performed after further incubation for 3 
hours50. 
 
21 
 
 
 
3.4. Antiproliferative assays in vitro. 
 
The antiproliferative activities of HIB, PdHIB and PtHIB were investigated over nine 
human cancer cell lines: U251 (glioma), UACC-62 (melanoma), MCF-7 (breast), NCI-
ADR/RES (multidrug resistant ovarian), NCI-H460 (lung, non-small cells), PC-3 (prostate), 
OVCAR-03 (ovarian), HT-29 (colon), K562 (leukemia). The tumor cell lines were provided by 
Frederick Cancer Research & Development Center, National Cancer Institute, Frederick, MA, 
USA, and a non-tumor cell line HaCat (human keratinocyte) used for cell viability was 
provided by Dr. Ricardo Della Coletta (University of Campinas- UNICAMP, Brazil). The same 
panel of cells were used previously in other assays performed in our group51. Such studies 
were developed in collaboration with Prof. Dr. Ana Lúcia Tasca Gois, form Chemical, 
Biological and Agricultural Pluridisciplinary Research Center (CPQBA-UNICAMP, Paulínia, 
Brazil), where the experiments were performed. 
Stock cultures were grown in 5 mL of RPMI-1640 supplemented with 5% fetal bovine 
serum (RPMI/FBS 5% Gibco®, USA) at 37°C in 5% CO2 with a 1% penicillin:streptomycin 
mixture (Nutricell®, Brazil, 1000 U·mL-1) (complete medium)52,53. The samples were prepared 
directly in complete medium (5 mg·mL-1) and then diluted in the same medium, affording the 
final concentrations of 0.25, 2.5, 25 and 250 μg·mL-1. K2PdCl4, K2PtCl4 and doxorubicin (final 
concentrations of 0.025, 0.25, 2.5 and 25 μg·mL-1 in complete medium) were used as 
controls.  
Cells in 96-well plates (100 μL cells/well, inoculation density: 3.5 to 6.0 x 104 cell/mL) 
were exposed to different concentrations of sample and controls (100 μL/well) in triplicate, 
for 48 h at 37°C and 5% of CO2. Before (T0 plate) and after the sample addition (T1 plates), 
cells were fixed with 50% trichloroacetic acid, and cell proliferation was determined by the 
spectrophotometric quantification (540 nm) of cellular protein content using the 
sulforhodamine B assay54. The GI50 values (concentration that inhibits 50% cell growth or 
cytostatic effect) were determined through non-linear regression, type sigmoidal, analyzed 
using Origin 8.0 software (OriginLab Corporation, USA)55.  
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3.5. Biophysical studies of interaction with DNA 
 
Calf thymus DNA (CT-DNA) was chosen as DNA model as it is widely used in studies 
of DNA binding anticancer agents that modulate DNA structure and function and because of 
its predominately double strand form. The CT-DNA was incubated for 24 h at 37 °C (100 
mol·L-1 CT-DNA aqueous solution in 10 mmol·L-1 NaClO4, 1% DMSO), with HIB, 
[PdCl2(HIB)2] and [PtCl2(HIB)2] in ratios [compound]/[DNA] of 0.1, 0.2 and 0.3 (10, 20 and 30 
mol·L-1). The solutions were used for circular dichroism spectroscopic experiments and for 
the fluorescence experiments with SYBR Green I®. Fluorescence measurements were 
performed on a Cary Eclipse fluorescence spectrophotometer. Excitation and emission slits 
were 5 nm and scanning speed was set to medium. A quartz cuvette of four clear windows 
and optical path length of 1.0 cm was used. SYBR Green I® (SG) was used as fluorescence 
probe. Excitation wavelength was set as 485 nm and emission window from 505 to 700 nm. 
For each sample the fluorescence at 520 nm (maximum for SG) was monitored with the 
consecutive addition of SG (4L of SG 5x). Circular dichroism (CD) measurements were 
performed in a Jasco J-720 spectrophotometer, from 205 to 320 nm, with a scanning speed 
of 20 nm·min-1 and 4 accumulations. The Quartz cuvettes of 1.0 cm of optical path length 
were used. 
 
3.6.  Synthesis 
 
3.6.1. Ibuprofen hydrazide (HIB). 
 
The synthesis of the Ibuprofen hydrazide was performed similarly to the methodology 
described inthe literature by Nakka et al.56 Ibuprofen (2.0x10-3 mol, 412.6 mg) was dissolved 
in 20 mL of dry dichloromethane and 300 L of trimethylamine (excess) were added to the 
solution. The solution was stirred for 5 minutes at room temperature and the flask was further 
transferred to an ice bath. To the cold solution, 200 L of methyl chloroformate (excess) were 
added and the solution was kept under stirring for 30 min before being transferred to a flask 
containing 500 L of hydrazine hydrate (H2NNH2·6H2O). This mixture was maintained under 
stirring and reflux (~50°C) for 3 hours and further 18 hours without heating. Finally, the 
reaction was quenched with 20 mL of distilled water and the volume of the resulting 
suspension was reduced under low pressure evaporation. The solid obtained was separated 
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by filtration, washed with cold water and dried under P4O10. Anal. Calcd. for C13H20N2O (%): 
C, 70.87; H, 9.15; N, 12.72. Found (%): C, 70.99; H, 9.24; N, 12.74. The yield of the synthesis 
was 71.0%. 
 
3.6.2.  PdHIB complex 
 
Potassium tetrachloropalladate(II) (2.5x10-4 mol) was first dissolved in a minimum 
amount of distilled water. To this solution was added HIB (5.0x10-4 mol) in 5 mL of methanol. 
Immediately a yellow solid precipitated and this mixture was kept under stirring for 2 hours. 
Finally, the solid was collected by filtration, washed with methanol and distilled water and 
dried under P4O10. Anal. Calcd. for PdC26H40N4O2Cl2 (%): C, 50.53; H, 6.52; N, 9.07. Found 
(%): C, 50.27; H, 6.48; N, 9.13. The yield of the synthesis was 84.7%. Single light yellow 
crystals suitable for X-ray diffraction studies were obtained by slow evaporation of an 
ethanolic solution of the complex.  
 
3.6.3. PtHIB complex.  
 
The synthesis of the platinum complex was similar to that of the palladium(II) one. 
Potassium tetrachloroplatinate(II) (2.5x10-4 mol) was first dissolved in distilled water and then 
added to a solution of HIB (5.0x10-4 mol) in 5 mL of methanol. After a few minutes a yellow 
solid precipitated and this mixture was kept under stirring for 20 hours. The solid obtained 
was separated by filtration, washed with methanol and distilled water and dried under P4O10. 
Anal. Calcd. for PtC26H40N4O2Cl2 (%): C, 44.19; H, 5.71; N, 7.93. Found (%):C, 45.39; H, 
5.53; N, 6.97. The yield of the synthesis was 65.8%. No single crystals were obtained even 
several attempts to perform a full X-ray crystallographic study. 
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4. Results and discussion 
 
4.1  Single crystal X-ray diffraction  
Crystals of PdHIB were obtained by recrystallization in ethanol and its structure was 
determined by single crystal X-ray diffraction. The crystallographic data are summarized in 
Table 1 and additional data are presented in Supplementary information (Table S1). 
The complex crystallized in the P21/c space group and the asymmetric part of the unit 
cell is presented in Figure 3(A). As one may observe, the asymmetric unit contains one Pd(II) 
ion, two chloride ions and two neutral HIB molecules. The complex possess a near perfect 
square geometry with the least square plane defined by those 4 ligands atoms with r.m.s of 
0.0290. The Pd1 ion is deviated 0.0154 Å from the plane defined from N1B, N1A, Cl1 and 
Cl2. The hydrazide groups of the HIB molecules coordinated trans to each other (N1A-Pd-
N1B = 178.58(12)°). In addition, two chloride ions complete the coordination sphere (Cl1-Pd-
Cl2 = 177.41(3)°).  
For similar Pd(II) and Pt(II) compounds reported in the literature57–62 the trans isomers 
were predicted by DFT calculations to be the most stable geometry, with the exception of the 
Pt(II) complexes with 4-methoxybenzylcarbazate, benzyl carbazate and 3-methoxybenzoic 
acid hydrazide63, in which the cis isomers are suggested. This feature indicates that other 
factors such as steric hindrance, ligand basicity as well as intermolecular interactions may be 
responsible for the additional stabilization of such system in comparison to cis-coordinated 
complexes. 
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Table 1. Crystallography data for PdHIB. 
Empirical formula C26H40Cl2N4O2Pd 
Formula weight (g·mol-1) 617.92 
T (K) 150 
γ(Mo Kα) (Å) 0.71073 
Crystal system Monoclinic 
Space group P21/c 
a (Å) 27.8148 (5) 
b (Å) 8.9319 (3) 
c (Å) 11.5187 (3) 
Β 92.462 (2) 
V (Å3) 2859.05 (13) 
Z 4 
Dx (Mg·m−3) 1.436 
μ (mm-¹) 0.865 
F(000) 1280 
Number Par./ Ind. Refl./ Rint 361/ 5855/ 0.037 
R[F2 > 2(F2)]; wR(F2); S 0.043; 0.103; 1.05 
max and min (e Å-3) 1.92 and -1.19 
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Figure 3. (A) View of asymmetric part of unit cell of the complex PdHIB. (B) Representation 
of the hydrogen bonds observed among the moieties [symmetry codes:(i) 1-x,-y,1-z, (ii) x, 
1/2-y, -1/2+z, (iii) 1-x, 1-y, 1-z]. For clarity, the disorder on the isopropyl group was 
intentionally not represented. Probability level of ellipsoids: 50%. 
An important feature observed in the crystal structure is the presence of both R and S 
configurations of HIB molecule (related to C2 chiral center) coordinated to Pd(II) ion. Since 
the ligand was synthesized from a racemic mixture of ibuprofen and no further racemic 
purification was performed, it is reasonable to suggest that both configurations would be 
present in the complex.  
Moreover, the bond lengths, angles and torsions among Pd(II) and its first sphere of 
coordination is close to those reported in the literature for a similar structure of palladium(II) 
complex with 2-thiophenecarboxylic hydrazide (see Supplementary information Tables S2 
and S3).64 Also, the bonds distances and angles from both HIB molecules (of the PdHIB 
crystal structure) are in good agreement with those observed for ibuprofen and ibuprofenate 
structures found on The Cambridge Structural Database (CSD) (see Supplementary 
information Tables S4 and S5). 
The presence of chlorine ions contribute to the packing of crystal structure since Cl1 
acts as receptor in two hydrogen bonds with N1bi (i=1-x,1-y,1-z) (D…A) (3.365(4)) and N1bii 
(ii=x,1/2-y,-1/2+z) ((D…A 3.484(4)) atom. The interaction with H1bb ((A…H 3.365(4)) is 
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forming a dimeric structure with another complex moiety while the interaction with H1ba atom 
forms a chain in the c direction. Besides it, the Cl2 ion appears as acceptor in other two 
hydrogen bonds formed with N1Aiii (D…A 3.197(3) iii=x,1/2-y,1/2+z) and N2biv (D…A 
3.157(4) iv=1-x,-y,1-z). Finally, the presence of the chlorine ions in the structure play an 
important role in the packing and stabilization of supramolecular structure. The packing of 
PdHIB in the crystal structure is shown in the representation of its unit cell (Figure 4). The 
views of the PdHIB packing through the axis x, y and z are shown in Supplementary 
information Figure S1. 
 
Figure 4. Representation of the unit cell of PdHIB. 
 
4.2  Infrared spectroscopy 
The IR spectra of the ligand and the complexes (PdHIB and PtHIB) are shown in Figure 
5. The NH2) vibrational modes, that appear at 1638 cm-1 in the spectrum of the ligand, are 
no longer observed in the spectra of the complexes due to coordination. Such observations 
confirm that coordination occurs by the NH2 65 as already observed in the crystal structure of 
PdHIB. 
Other important information about coordination were obtained by infrared spectroscopy. 
For the ligand, the absorption corresponding to N–H) is observed at 3271 cm-1 and it is 
shifted to 3239 cm-1 and 3251 cm-1 for PdHIB and PtHIB, respectively. It occurs since 
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coordination to Pd(II) or Pt(II) (Lewis acids) reduces the electron density in the N–H bond 
(near the coordination site), thus this vibration occurs in lower energy values in the complexes 
than in the free ligand.  
Similarly as discussed above, the C=O) absorption is observed at 1687 cm-1 in the 
ligand and it is shifted to 1668 cm-1 in the PdHIB spectrum and to 1666 cm-1 for PtHIB due to 
change of electron density induced by coordination. The region between 2960 and 2850               
cm-1, which contains the C–H) stretches, is identical in all three spectra, since the 
coordination occurs in a nitrogen far from C–H bonds.65,66 
 
Figure 5. Infrared spectra of HIB (A), PdHIB (B) and PtHIB (C). 
 
4.3 Thermogravimetric and differential thermal analyses (TG/DTA) 
 
Thermogravimetric (TGA) and differential thermal analyses (DTA) were performed in 
oxidant atmosphere and the data obtained are shown in Figure 6. For the PdHIB complex 
the loss of two ligands plus 2Cl- ions is observed from 130°C to 450°C. Calc. for loss of 2 HIB 
29 
 
 
 
plus 2Cl ligands (%) 82.7; found (%) 80.2. The percentage of residue is coherent with Pd°. 
Calc. for Pd° (%) 17.3; found (%) 19.8.  
Similarly, the profile of the TG/DTA curves of PtHIB shows the loss of the two HIB 
ligands between 122°C and 375°C. Calc. for loss of 2 HIB plus 2 Cl ligands (%) 72.4; found 
(%) 70.2. The percentage of residue is coherent with Pt°. Calc. for Pt° (%) 27.6; found (%) 
29.2.  
These results reinforce the composition of the complexes suggested by elemental 
analyses, being [PdCl2(C13H20N2O)2] and [PtCl2(C13H20N2O)2]. 
 
 
Figure 6. TG (blue) and DTA (black) curves for PdHIB (A) and PtHIB (B) 
 
4.4  Stability in solution 
 
The UV-Vis spectra of the ligand HIB in methanol shows an intense absorption band 
with a maximum at 227 nm. In the same region, there are bands from the ligand in PdHIB 
and PtHIB, as presented in Figure 7. 
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Figure 7. UV spectra of HIB, PdHIB and PtHIB in methanol. 
 
The UV-Vis spectroscopy was used to evaluate the stability of PdHIB and PtHIB in 
solutions of DMSO and methanol. The spectra were recorded every 30 minutes for 22 hours 
in the wavelength range of 200-400 nm and they are presented in Figure 8. The solutions in 
methanol and DMSO are in concentrations of 133 mol·L-1 and 200 mol·L-1, respectively. 
The spectra in DMSO are presented in a different range due to the DMSO interference. 
It was determined that PtHIB is not stable in DMSO (Figure 8C), as there were 
significant changes the spectrum noticed by the maximum absorbance that increased from 
0.8 to values higher than 1.0, probably because of ligand exchange. This is not observed in 
the kinetic studies of the other samples shown in Figure 8. 
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Figure 8. UV-Vis spectra of PdHIB in DMSO (A), PdHIB in MeOH (B), PtHIB in DMSO (C) 
and PtHIB in MeOH (D) in the time range from 0 to 22 hours. 
 
4.5 NMR spectroscopy 
 
The characterization of the ligand and complexes was also performed by solution NMR, 
including 1H, 13C, {13C,1H} HSQC (heteronuclear single quantum coherence), {13C,1H} HMBC 
(heteronuclear multiple bond coherence), {15N,1H} HSQC and {15N,1H} HMBC NMR in DMSO-
d6 and methanol-d4. In addition, 15N and 13C solid state NMR using CP-MAS (cross 
polarization and magic angle spinning) technique were also applied to the study of the 
complexes.  
 In the 1H NMR spectrum of HIB in DMSO-d6 it was possible to see the signals of the 
hydrogen atoms bonded to the nitrogen atoms (Figure 9) that were confirmed by {15N,1H} 
HSQC (Figure 10). The integrated intensity of these hydrogens signals are also in agreement 
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with two hydrogens for NH2 (Relative intensity = 1.89) and one hydrogen for NH (Relative 
intensity = 0.94). 
 
Figure 9. 1H NMR spectrum of HIB in DMSO-d6. On top of the peaks are shown the 
chemical shifts and at the bottom are the integrated intensities. An expansion from 1.7 to 
3.5 ppm is presented on the top left corner. 
 
 
Figure 10. {15N,1H} HSQC NMR spectrum of HIB in DMSO. The chemical shifts of the 
nitrogen atoms are shown.    
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 Figures 11-13 show the 1H, {13C,1H} HSQC and {13C,1H} HMBC NMR spectra of HIB 
in Methanol-d6 (MeOD) with the attributions of all the C and H atoms. Carbons named C3 
and C8 were unequivocally assigned by the {13C,1H} HMBC technique. It was possible 
because in this spectra C3 has multiple bond correlations to H13 and H2, while C8 correlates 
to H9. The hydrogens of the groups NH and NH2 are not observed in MeOD solution because 
they are able to exchange with the deuterium of the hydroxyl group due to their lability, 
therefore broadening the signal. It does not happen in DMSO-d6 solution as this solvent lacks 
a more labile hydrogen. 
Also, note that hydrogens H4 and H6 are equivalent by symmetry, as are the pairs H5-
H7 and H11-H12 in all the 1H NMR because of the free rotation of the aromatic ring and 
isopropyl group in solution.  
 
 
Figure 11. 1H NMR spectrum of HIB in MeOD. On top of the peaks are shown the 
chemical shifts and in the bottom are the calculated integrals. An expansion from 1.6 to 2.1 
ppm highlights the signal of the hydrogen H10. 
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Figure 12. NMR spectrum of HIB {13C,1H} HSQC in MeOD. 
 
 
Figure 13. NMR spectrum of HIB {13C,1H} HMBC in MeOD. 
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It was observed that PdHIB and PtHIB behave differently in solution, as expected. The 
PtHIB NMR spectrum in DMSO-d6 shows decomposition of the complex within few minutes, 
while PdHIB was stable in DMSO-d6 even after 10 days, which confirms the stability 
suggested in the UV-Vis experiments. Figure 14 shows the {13C,1H} HMBC NMR spectrum 
of PdHIB in DMSO-d6 and Figure 15 shows the equivalent spectrum for PtHIB in MeOD. 
 
 
Figure 14. NMR spectrum of PdHIB {13C,1H} HMBC in DMSO-d6. 
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Figure 15. NMR spectrum of PtHIB {13C,1H} HMBC in MeOD. 
 
The use of solid state NMR was necessary to characterize the complexes as the 
nitrogen atoms could not be observed in solution. Furthermore, the analysis in the solid state 
gave a fair representation of both complexes, independent of the solvents. Table 2 shows the 
chemical shift in the 13C and 15N SSNMR spectra of HIB, PdHIB and PtHIB.  
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Table 2. Chemical shifts in the 13C and 15N SSNMR for HIB, PdHIB and PtHIB.  
Chemical shifts (ppm) 
 Carbon numbers Nitrogen atoms 
 13 11/12 10 2 9 4 /5/6 /7 3 8 1 NH NH2 
HIB 17.3 24.8 31.7 43.6 46.6 129.9 140.9 140.9 179.6 
127.2 
134.4 
56.3 
PdHIB 19.9 23.8 
31.0 
31.9 
44.2 45.0 128.6 138.3 139.9 175.0 
131.1 
136.0 
139.5 
11.7 
18.1 
PtHIB 18.2 22.7 30.4 45.1 45.1 129.2 139.6 139.6 173.5 138.1 9.7 
 
 
The main difference in chemical shifts between the spectrum of HIB and the spectra of 
the complexes is in the nitrogen of the NH2 group, which is shifted from 56.3 ppm for HIB to 
11.7-18.1 ppm for PdHIB and 9.7 ppm for PtHIB as presented in Figure 16. This is an 
evidence that coordination to Pd(II) and Pt(II) occurs by the NH2 of the hydrazide group. 
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Figure 16. 15N SSNMR spectra of HIB (A), PdHIB (B) and PtHIB (C). 
 
4.6 Mass spectrometric measurements 
 
The mass spectrum of PdHIB (Figure 17) presents the ion [Pd(HIB)2Cl]+ at m/z 
583.1874 (error 32.6 ppm) as the most intense peak, but it also shows the ion [Pd(HIB)2 - H]+ 
at m/z 545.2149, which refers the complex with one of the ligands bearing a negative charge 
due to deprotonation. Furthermore, the signal at m/z 221.1735 corresponding to the 
protonated ligand [HIB+H]+ is observed. Additional patterns of species containing Pd ions are 
also present, such as [Pd(HIB)3Cl]+ at m/z 801.3544, [Pd2(HIB)3 - 3H]+ at m/z 871.2578, 
[Pd2HIB3Cl - 2H]+ at m/z 907.2196 and [Pd2HIB3Cl2 - H]+ at 943.2081. 
For PtHIB complex (Figure 18) the results are similar, with the ions [Pt(HIB)2Cl]+ at m/z 
671.2528 (error 9.2 ppm), [Pt(HIB)2 - H]+ at m/z 634.2934, [Pt(HIB)2 - H + DMSO]+ at m/z 
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712.2815 and [Pt(HIB)3 - H]+ at m/z 854.4240. The signal corresponding to the protonated 
ligand is also observed.  
 
 
Figure 17. (A) Mass spectra for the PdHIB complex from 100 to 1000 m/z. (B) Theoretical 
isotope pattern for the complex [Pd(HIB)2Cl]+. (C) ESI(+)-QTOF mass spectrum of PdHIB 
from 576 to 590 m/z.  
 
 
Figure 18. (A) Mass spectra for the PtHIB complex from 100 to 1000 m/z. (B) Theoretical 
isotope pattern for the complex [Pt(HIB)2Cl]+. (C) ESI(+)-QTOF mass spectrum of PtHIB from 
668 to 680 m/z.  
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4.7 DFT calculations  
 
The geometric calculations for PdHIB and PtHIB complexes were optimized using 
density functional theory (DFT). The DFT data, including the atomic coordinates for the 
optimized structures, are presented in Supplementary Information - Tables S6 and S7.  
As previously observed, the crystal structure of the Pd(II) complex is composed of one 
Pd(II) coordinated by two neutral HIB molecules and two chloride ions. The elemental 
analysis, as well as the ESI-QTOF-MS of the Pd(II) complex in its powder form, indicate that 
the same composition is observed in the crystal and powder samples. In addition, the same 
studies regarding the Pt(II) complex indicate that it also possesses a 1:2:2 metal/HIB/chloride 
ratio, as observed for the Pd(II) complex. Moreover, the SSNMR and IR spectroscopic 
measurements of the powder samples indicate that, for both complexes, the coordination 
occurs by the hydrazide moieties of HIB. Therefore, it is reasonable to assume that the Pt(II) 
complex is coordinated by HIB in the same fashion as observed in the PdHIB crystal 
structure. The DFT optimized structure of PtHIB and PdHIB are represented in Figures 19 
and 20. 
 
 
Figure 19. PBE0/def2-TZVP optimized structure of [PtCl2(HIB)2]. 
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Figure 20. PBE0/def2-TZVP optimized structure of [PdCl2(HIB)2]. 
In a different way of the optimized structure of the Pt(II) complex, in which the HIB 
molecules are arranged in a similar fashion to PdHIB crystal structure, the HIB ligands on 
DFT optimized structure of the Pd(II) complex are arranged at different positions (see Figure 
21). The planes formed among the carbon atoms of the benzyl ring of the HIB molecules in 
the crystal structure are observed displaced by 80.15° and 30.07° of their respective planes 
in the DFT optimized structure. Since intermolecular interactions are observed in the crystal 
structure that could not be otherwise simulated by the DFT model (which considers a single 
molecule in vacuum), it is reasonable to assume that the most thermodynamically stable 
structure obtained by DFT can be different to that observed in the crystal.  
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Figure 21 - Comparison between the crystal structure of [PdCl2(HIB)2] and its optimized 
structure by DFT. The structures were overlapped considering the common positions of the 
metal ion and its first coordination sphere. The crystal structure is represented as ellipsoids 
and the DFT structure is represented as sticks. The hydrogen atoms were intentionally 
omitted. 
Apart from this difference between crystal structure of PdHIB and its optimized structure 
by DFT, both optimized structures of Pd(II) and Pt(II) complexes possess HIB ligands with 
bond lengths and angles similar to those observed in the crystal structure of the Pd(II) 
complex (see Supplementary information - Table S8). Furthermore, as one may observe in 
Table 3, the bond distances for Pd(II) and the ligand atoms are very close to the values 
observed in the crystal structure. On the other hand, for PtHIB the same selected bonds were 
compared to the crystal structure of a similar complex previously reported in the literature 
(dichloro(1,6-diaminotetrahydropyrrolo[2,3-b]pyrrole-2,5(1H,4H)-dione)platinum(II))67. Again, 
the bond lengths for the Pt(II) complex are very close to those observed in the literature.  
The DFT optimized structures of PdHIB and PtHIB were also compared with other DFT 
optimized structures found in the literature for Pd(II) and Pt(II) complexes that have NH2 
moieties coordinated in trans geometry (Table 3). It is interesting to notice that in these 
complexes the Pd-N bond lengths calculated using the PBE0 hybrid functional are very 
similar to each other and to the distances reported in the crystal structures. On the other 
hand, the same lengths calculated using the B3LYP functional are generally longer, 
suggesting that the functional PBE0 better predicts this kind of coordination bond. 
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Table 3. Selected bond lengths for the Pd(II) and Pt(II) complexes in comparison to the 
literature and to the crystal structure of [PdCl2(HIB)2]. The bond lengths calculated by DFT 
are presented in average. 
 
  
M-Cl2/  
M-Cl1*  
M-N1B/  
M-N1A 
N1B-N2B/ 
N1A-N2A 
C1B-O1B/ 
C1A-O1A 
[PdCl2(HIB)2] crystal 
2.2889(9)/ 
2.309(1) 
2.048(3)/ 
2.036(3) 
1.408(4)/ 
1.425(4) 
1.226(5)/ 
1.224(4) 
[PdCl2(HIB)2] DFT 2.307‡ 2.046‡ 1.406‡ 1.214‡ 
[PdCl2(C10H12N2)2] 58 2.337‡ 2.049‡ - - 
[PdCl2(L)2]** 61 2.34‡ 2.07‡ - - 
[Pd(C6H10NO3S)2] 60 - 2.089† - - 
[Pd(C11H11N2O2)2] 57 - 2.08† - - 
[Pd(C6H10NO2S)2] 59 - 2.11† - - 
Pt(II) complex§ crystal 
2.296(2)/ 
2.299(2) 
2.051(5)/ 
2.028(6) 
1.416(8)/ 
1.419(9) 
1.227(5)/ 
1.210(9) 
[PtCl2(HIB)2] DFT 2.308‡ 2.049‡ 1.407‡ 1.215‡ 
[Pt(C11H11N2O2)2] 62 - 2.08† - - 
* M refers to the dicationic metal ion, M(II) (i.e. Pd(II) or Pt(II)). 
** L refers to carbazates and hydrazides (mean value). 
§ Z. Kristallogr. 209 (1994) 293.67 
‡ calculated using the PBE0 functional 
† calculated using the B3LYP functional 
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4.8 Biological assays 
 
4.8.1 Minimal inhibitory concentration (MIC) 
The PdHIB and PtHIB complexes were not able to inhibit the growth of any bacteria in 
the concentrations tested. However, HIB was able to inhibit S. aureus (ATCC 25923) and E. 
coli (ATCC – 25922) in the MICs of 1850 µg·mL-1 and 3750 µg·mL-1, respectively. These 
results are interesting since free ibuprofen does not possess any antibacterial activity, but 
when the COOH group is replaced by a CONHNH2 group the compound is active. The fact 
that the complexes do not possess antibacterial activities may indicate that free CONHNH2 
group is determinant for the antibacterial activity, since the coordination occurs by this group 
and the complexes are inactive.  
 
4.8.2 Antiproliferative assays 
The antiproliferative activities of HIB as well as PdHIB and PtHIB complexes were 
evaluated over a panel of human tumor cells. Doxorubicin, a frontline drug used for the 
treatment of several types of cancer 68, was used as positive control and the precursor salts, 
K2[PdCl4] and K2[PtCl4], were also evaluated. This activity was expressed as the parameter 
GI50 representing the sample concentration necessary to inhibit 50% of cell growth, therefore 
a low GI50 means a high antiproliferative activity. The results are reported by estimated 
concentration (μmol·L-1) (Table 4), as the compounds were suspended in water and added 
to the biological medium (no DMSO was used to improve PdHIB and PtHIB solubility). 
The Pt(II) complex presented GI50 values higher than 353.2 μmol·L-1 for all the cell lines. 
On the other hand, the PdHIB complex showed selective inhibition against the ovarian cancer 
cell line (OVCAR-03, GI50 = 27.0 μmol·L-1) (Table 4). Another important aspect of 
antiproliferative activity is the selectivity towards cancer and normal cells. Experimentally, this 
selectivity can be estimated using a selectivity index (SI), defined as 69:  
SI =  
GI50 (𝐻𝑎𝐶𝑎𝑡)
GI50 (𝑐𝑎𝑛𝑐𝑒𝑟 𝑐𝑒𝑙𝑙 𝑙𝑖𝑛𝑒)
 
Where GI50 (HaCat) is the GI50 for the non-tumor human cell line (immortalized 
keratinocytes) and GI50 (cancer cell line) is the GI50 value for a given cancer cell line. Hypothetically, 
the higher the value of SI the higher the dose that could be administered safely 69. The values 
of SI calculated for each cell line are presented in Table 4. Antiproliferative profiles are 
presented in the Supplementary information - Figures S2 - S7. 
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Table 4. GI50 (μmol·L-1) and selectivity index (SI) values obtained for HIB, [PdCl2(HIB)2], 
[PtCl2(HIB)2], K2[PdCl4], K2[PtCl4] and doxorubicin in the in vitro antiproliferative assay. 
 
GI50: concentration that inhibits 50% cell growth or cytostatic effect after 48h-exposition.  
Tumor human cell lines: U251 = glioma, UACC-62 = melanoma; MCF-7 = breast; NCI-ADR/RES = 
multidrug resistant ovarian; NCI-H460 = lung, non-small cells; PC-3 = prostate; OVCAR-03 = ovarian; 
HT-29 = colon; K562 = leukemia; Non-tumor human line: HaCat = immortal keratinocyte; Doxo = 
Doxorubicin. 
* The values of GI50 were not reached in the concentrations tested. 
** SI values could not be calculated as GI50 (HaCat) and GI50 (cancer cell lines) are lower than 0.05 mol·L-1.  
 
  
GI50 (mol·L-1) 
  U251 UACC-62 MCF-7 
 NCI-
ADR/RES 
 NCI-
H460 
PC-3 OVCAR-03 HT-29  K562 HaCat 
HIB 511.10 144.34 171.12 * * 521.54 92.14 * 119.83 217.42 
PdHIB * * * * * * 27.02 * * >404.6 
PtHIB * * * * * * * * * 353.24 
K2PdCl4 99.25 10.72 96.50 90.68 117.94 96.80 11.33 96.80 85.16 82.71 
K2PtCl4 64.08 4.09 61.91 20.23 57.81 20.71 23.37 66.49 59.02 6.99 
Doxo <0.045 <0.045 <0.045 0.46 <0.045 0.42 0.092 0.26 0.055 <0.045 
Selectivity Index (SI) 
  U251 UACC-62 MCF-7 
 NCI-
ADR/RES 
 NCI-
H460 
PC-3 OVCAR-03 HT-29  K562   
HIB 0.43 1.51 1.27 * * 0.42 2.36 * 1.81   
PdHIB * * * * * * >14.97 * *   
PtHIB * * * * * * * * *   
K2PdCl4 0.83 7.71 0.86 0.91 0.70 0.85 7.30 0.85 0.97   
K2PtCl4 0.11 1.71 0.11 0.35 0.12 0.34 0.30 0.11 0.12   
Doxo ** ** ** <0.09 ** <0.11 <0.49 <0.17 <0.81   
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Considering the ovarian cancer cell line (OVCAR-03), PdHIB has shown a SI equal to 
14.97, which is higher than that of doxorubicin (SI ≤ 0.49), K2PdCl4 (SI = 7.30) and K2PtCl4 
(SI = 0.30). Although the activity of [PdCl2(HIB)2] was lower than doxorubicin, its selectivity 
towards cancer cells was noticeable. The activity observed against OVCAR-3 is particularly 
interesting once this cell line is used as a model for cisplatin resistance in ovarian cancer 
70,71. In addition, HIB showed low activity against the cell lines tested, but its SI was higher 
than 1.0 for the cancer cell lines UACC-62 (melanoma), MCF-7 (breast), OVCAR-03 (ovarian) 
and K562 (leukemia). 
When discussing the pharmacological potential of a molecule, we have to consider 
that each drug has a therapeutic window, or safety window, which is the range of 
concentration (dosage) that provides the desired efficiency with acceptable side effects. 
Specially in the case of cancer chemotherapy, the side effects are more acceptable due to 
the aggressive nature of the disease. That is why chemotherapy with cisplatin or doxorubicin 
are so aggressive, showing several side effects and considerably weakening the patient's 
health. However, such drugs are able to treat cancer with high efficiency. 
 The SI is a parameter that merely is related to the therapeutic window, therefore 
should be interpreted carefully. Hypothetically, the effective dosage of PdHIB to treat a patient 
with ovarian cancer would be much higher than doxorubicin or cisplatin, Nevertheless, a high 
dose of the complex would not be toxic and most of the side effects could be avoided.  
 
4.9 Biophysical studies: interaction with DNA 
 
The interactions between bio-macromolecules and pharmacological agents have 
attracted special interest among both chemistry and biology researchers during the past few 
decades.72 Given that DNA is an important target for cisplatin and many metal complexes, 
the interaction between them have been studied extensively 73–77. Damage caused by 
anticancer agents in the DNA of cancer cells may block their division and lead to cell death78. 
The interaction with DNA may occur in various ways including covalent binding and non-
covalent modes such as intercalation, groove binding and electrostatic interaction. To 
investigate the presence of these interactions, several techniques are available, including UV 
spectrophotometry, circular dichroism spectroscopy and fluorescence studies with DNA 
intercalators 79–83. 
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4.9.1 Fluorescence studies with SYBR Green (SG) 
 
SYBR Green (Figure 22) is a specific fluorophore that effectively interacts with double 
strand DNA, more specifically in the DNA minor groove84, increasing its fluorescence 
emission upon complex formation by >1,000-fold85.  
 
  
Figure 22. Molecular structure of SYBR Green. 
 
It is possible to study the interaction of a compound with DNA by observing the reduction 
of the fluorescence emission intensity of SG due to competition and/or blocking of interaction 
by the molecule of interest. 
As already presented, CT-DNA was incubated for 24 h at 37°C with HIB, PdHIB and 
PtHIB in the ratios (compound/DNA) of 0.1, 0.2 and 0.3. For each sample the fluorescence 
at 520 nm (maximum of SG) was monitored with the consecutive addition of SG (4L of SG 
10x). The results are shown in Figure 23. The fluorescence is presented relatively to the 
maximum intensity obtained for the free DNA in the presence of SG. It was necessary to 
normalize the errors due to experiments done in different days. The fluorescence of SG alone 
was measured and it is insignificant, thus not reported. 
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Figure 23. Relative fluorescence intensities of SG at 250 nm for samples of free DNA and 
DNA in the presence of PdHIB in the ratios (compound/DNA) 0.1, 0.2, 0.3. 
 
For the samples of DNA incubated with HIB and PtHIB no significant fluorescence 
suppression is observed for all the concentrations tested. However, the samples of DNA 
incubated with PdHIB have a different profile. For the ratios of 0.2 and 0.3 the fluorescence 
intensity was decreased significantly suggesting interactions with DNA for ratios higher than 
0.1, which seems to partially blocks SG interaction. The fluorescence suppression observed 
for this experiment may be a result of intercalation of PdHIB between the DNA bases or 
interaction with the DNA groove.  
 
4.9.2 Circular dichroism spectroscopy 
 
Circular dichroism spectroscopy is widely used to monitor conformational polymorphism 
of DNA, among many other aplications82,83. This technique is not able to provide information 
of molecules interacting with DNA at atomic level, for this reason, CD spectroscopy is 
primarily used empirically in studies with DNA. It is possible to differentiate DNA 
conformational changes between B-form, A-form, Z-form and other structures due to 
interactions with different compounds. The CT-DNA is characteristically a B-form right-
handed DNA as shows the CD spectrum (Figure 24), where there is a positive band at 275 
nm due to base stacking and negative band at 245 nm attributed to helicity82,86. In addition, 
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a positive band at 220 nm is also observed83,87. It was observed that HIB and PtHIB did not 
induce any noticeable changes in the CD spectrum even in the highest ratio tested.  
The PdHIB complex, on the other hand, seems to alter the DNA conformation in the 
ratios 0.2 and 0.3 (Compound/DNA). In Figure 24, a comparison between the CD spectrum 
of CT-DNA in the absence and presence of PdHIB is presented. 
For RI=0.1 it is observed a decrease in the intensity of all the bands and a slightly 
bathochromic shift, but the spectrum is still characteristic of a B-form DNA. However, for RI= 
0.2 and RI=0.3 the CT-DNA suffers a significant destabilization of the B-form. The band 
intensities decreased and there is a great shift in the band at 275 nm suggesting alteration of 
the staking probably due to intercalation or covalent binding. Furthermore, the changes in the 
band at 245 nm indicate that the complex modify the helicity of DNA73. 
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Figure 24. CD spectra of CT-DNA in absence and presence of PdHIB in the ratios (complex/ 
DNA) of 0.1, 0.2 and 0.3. The vertical bars represent the experimental error between three 
measurements. 
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5. Conclusions 
 
Pd(II) and Pt(II) complexes with HIB were obtained with the coordination formulas 
[PdCl2(C13H20N2O)2] and [PtCl2(C13H20N2O)2] (1:2:2 metal/ ligand/ chloride). The compounds 
were characterized by mass spectrometry, and infrared and nuclear magnetic resonance 
spectroscopies. It was observed that the coordination of the ligand to the metal ions occurs 
by the nitrogen of the NH2 group in a trans geometry. The structure of the PdHIB complex 
was solved by single-crystal X-ray diffraction studies. 
Crystals suitable for X-ray diffraction were not obtained for PtHIB, however, its structural 
formula was suggested considering the spectroscopic data and DFT calculations. The DFT 
optimized structures of PdHIB and PtHIB were compared with the crystal structure of PdHIB 
and other similar crystals reported in the literature. It was shown that, not only the bond 
lengths and angles of the optimized structures were in accordance with the expected ones 
considering the crystal structure of the Pd(II) complex and others from the literature, but also 
that the functional PBE0 predicts this kind of coordination mode more appropriately than the 
B3LYP functional, which is frequently used by other authors. 
The HIB was evaluated concerning its antibacterial and antiproliferative activities.88 The 
MIC assay of HIB showed its in vitro activity against strains S. aureus (ATCC 25923) and E. 
coli (ATCC 25922) in the concentrations of 1850 µg·mL-1 and 3750 µg·mL-1, respectively. 
HIB also showed in vitro antiproliferative activity against six cancer cell lines in the micro 
molar range (92.14 – 511.10 mol·L-1). It is interesting to notice that ibuprofen does not have 
antiproliferative or antibacterial properties, therefore the derivatization of ibuprofen to a 
hydrazide (HIB) was able to change some of its biological properties. The presence of free 
NHNH2 moiety seems to be determinant for the activity of the compound. 
On the other hand, the complexes were not active against the considered bacterial 
strains in the concentrations tested, and only PdHIB showed noticeable in vitro 
antiproliferative activity against ovarian cancer cell line (OVCAR-03) with GI50 27.02 mol·L-
1. Interestingly, the PdHIB estimated selectivity index (SI) for OVCAR-03 was the higher 
observed in the experiment (TI > 14.97). This is because PdHIB inhibited the growth of the 
non-tumor cell line HaCat in a considerable higher concentration (GI50 > 404.6 mol·L-1), 
which is an indication that the complex would be potentially safer to be administered in vivo. 
The low toxicity of PdHIB against normal cell lines is interesting as the systematic toxicity of 
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metal based drugs is currently a challenge in the medical clinic. Further preclinical and in vivo 
assays are needed to validate such hypothesis. 
The overall low activities observed in the antiproliferative assays of the complexes may 
be attributed to the low solubility in the culture medium, even though low solubility of a metal 
complex is not necessarily a case of concern. For example, cisplatin is very insoluble in water, 
however it is administrated in a solution containing NaCl, NaOH and HCl in H2O to assure a 
better solubility. The PdHIB complex could be further studied, for example, in a nano 
encapsulated formulation that would provide higher solubility and increased distribution in 
biological medium to evaluate the increase or decrease of activity and selectivity towards 
cancer cells. 
The ligand and the respective complexes were evaluated concerning their interaction 
with CT-DNA. Only PdHIB showed a considerable interaction with DNA, by intercalation or 
covalent bond, causing structural changes as evidenced by CD spectroscopy. This 
interaction was also indicated by fluorescence studies of competitive interaction to DNA using 
SG probe, as the fluorescence intensity of SG with CT-DNA was decreased by the presence 
of PdHIB. This suggests that the higher antiproliferative activity of PdHIB in comparison to 
PtHIB is due to the former’s capacity of interaction with DNA, which is the main target for this 
kind of metallodrugs. The interaction of PdHIB (and not PtHIB) with DNA could be explained 
by the differences on reactivity between the Pd(II) and the analogous Pt(II) complexes, as 
Pd(II) complexes usually have faster reaction kinetics and could react with DNA promptly. 
Also, the lower solubility of PtHIB could have hampered its interaction with the DNA, as the 
complex availability in solution is inferior. 
 
 
  
52 
 
 
 
 
6. Bibliographic references  
 
1. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000). 
2. Yang, E. J., Wu, C., Liu, Y., Lv, J. & Sup Shim, J. Revisiting Non-Cancer Drugs for Cancer 
Therapy. Curr. Top. Med. Chem. 16, 2144–2155 (2016). 
3. Biemar, F. & Foti, M. Global progress against cancer-challenges and opportunities. Cancer 
Biol. Med. 10, 183–186 (2013). 
4. Zugazagoitia, J. et al. Current Challenges in Cancer Treatment. Clin. Ther. 38, 1551–1566 
(2016). 
5. Rosenberg, B., Van Camp, L. & Krigas, T. Inhibition of Cell Division in Escherichia coli by 
Electrolysis Products from a Platinum Electrode. Nature 205, 698–699 (1965). 
6. Rosenberg, B., Van Camp, L., Trosko, J. & Mansour, V. Platinum Compounds: a New Class 
of Potent Antitumour Agents. Nature 222, 385–386 (1969). 
7. Medici, S. et al. Noble metals in medicine: Latest advances. Coord. Chem. Rev. 284, 329–
350 (2015). 
8. Wheate, N. J., Walker, S., Craig, G. E. & Oun, R. The status of platinum anticancer drugs in 
the clinic and in clinical trials. Dalt. Trans. 39, 8113–8127 (2010). 
9. Pinato, O., Musetti, C. & Sissi, C. Pt-based drugs: the spotlight will be on proteins. 
Metallomics 6, 380–395 (2014). 
10. Ramachandran, S., Quist, A. P., Kumar, S. & Lal, R. Cisplatin Nanoliposomes for Cancer 
Therapy: AFM and Fluorescence Imaging of Cisplatin Encapsulation, Stability, Cellular 
Uptake, and Toxicity. Langmuir 22, 8156–8162 (2006). 
11. Wang, X., Wang, X. & Guo, Z. Functionalization of Platinum Complexes for Biomedical 
Applications. Acc. Chem. Res. 48, 2622–2631 (2015). 
12. Apps, M. G., Choi, E. H. Y. & Wheate, N. J. The state-of-play and future of platinum drugs. 
Endocr. Relat. Cancer 22, R219–R233 (2015). 
13. Neidle, S., Ismail, I. M. & Sadler, P. J. The structure of the antitumor complex cis-(diammino) 
(1,1-cyclobutanedicarboxylato)-Pt(II): X ray and NMR studies. J. Inorg. Biochem. 13, 205–
212 (1980). 
14. Frey, U., Ranford, J. D. & Sadler, P. J. Ring-Opening Reactions of the Anticancer Drug 
Carboplatin: NMR Characterization of cis-[Pt(NH3)2(CBDCA-O)(5′-GMP-N7)] in Solution. 
Inorg. Chem. 32, 1333–1340 (1993). 
15. Kasparkova, J., Vojtiskova, M., Natile, G. & Brabec, V. Unique properties of DNA interstrand 
cross-links of antitumor oxaliplatin and the effect of chirality of the carrier ligand. Chem. - A 
Eur. J. 14, 1330–1341 (2008). 
16. Coluccia, M. & Natile, G. Trans-Platinum Complexes in Cancer Therapy. Anticancer. Agents 
53 
 
 
 
Med. Chem. 7, 111–123 (2007). 
17. Peterson, E. J. et al. Antiangiogenic platinum through glycan targeting. Chem. Sci. 8, 241–
252 (2017). 
18. Farrell, N. P. Multi-platinum anti-cancer agents. Substitution-inert compounds for tumor 
selectivity and new targets. Chem. Soc. Rev. 44, 8773–8785 (2015). 
19. Qu, Y., Kipping, R. G. & Farrell, N. P. Solution studies on DNA interactions of substitution-
inert platinum complexes mediated via the phosphate clamp. Dalt. Trans. 44, 3563–3572 
(2015). 
20. de Souza, G. D. et al. A New Complex of Palladium(II) With 2-Furoic Hydrazide: Synthesis, 
Characterization, Theoretical Calculations and Biological Studies. Croat. Chem. Acta 86, 
201–206 (2013). 
21. Garoufis, A., Hadjikakou, S. K. & Hadjiliadis, N. Palladium coordination compounds as anti-
viral, anti-fungal, anti-microbial and anti-tumor agents. Coord. Chem. Rev. 253, 1384–1397 
(2009). 
22. Harris, R. E., Beebe-Donk, J., Doss, H. & Burr Doss, D. Aspirin, ibuprofen, and other non-
steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-
2 blockade. Oncol. Rep. 13, 559–583 (2005). 
23. Rayburn, E. R., Ezell, S. J. & Zhang, R. Anti-Inflammatory Agents for Cancer Therapy. Mol. 
Cell 1, 29–43 (2009). 
24. Baron, J. A. & Sandler, R. S. Nonsteroidal Anti-Inflammatory drugs and Cancer Prevention. 
Annu. Rev. Med. 51, 511–523 (2000). 
25. Qu, X. et al. Hydrolysis of ibuprofenoyl-CoA and other 2-APA-CoA esters by human acyl-CoA 
thioesterases-1 and -2 and their possible role in the chiral inversion of profens. Biochem. 
Pharmacol. 86, 1621–1625 (2013). 
26. Lloyd, M. D. et al. a-Methylacyl-CoA racemase (AMACR): Metabolic enzyme, drug 
metabolizer and cancer marker P504S. Prog. Lipid Res. 52, 220–230 (2013). 
27. Park, S.-S. et al. P504S expressing circulating prostate cells as a marker for prostate cancer. 
Oncol. Rep. 24, 687–692 (2010). 
28. Evans, A. J. Alpha-methylacyl CoA racemase (P504S): overview and potential uses in 
diagnostic pathology as applied to prostate needle biopsies. J. Clin. Pathol. 56, 892–897 
(2003). 
29. Kokki, H. Nonsteroidal anti-inflammatory drugs for postoperative pain: a focus on children. 
Paediatr. Drugs 5, 103–123 (2003). 
30. Pereira E Silva, I. M. et al. A silver complex with ibuprofen: Synthesis, solid state 
characterization, DFT calculations and antibacterial assays. J. Mol. Struct. 1049, 1–6 (2013). 
31. Fiori, A. T. M., Lustri, W. R., Magalhães, A. & Corbi, P. P. Chemical, spectroscopic 
characterization and antibacterial activities in vitro of a novel gold(I)-ibuprofen complex. Inorg. 
54 
 
 
 
Chem. Commun. 14, 738–740 (2011). 
32. Dendrinou-Samara, C. et al. Anti-inflammatory drugs interacting with Zn(II), Cd(II) and Pt(II) 
metal ions. J. Inorg. Biochem. 71, 171–179 (1998). 
33. Trinchero, A., Bonora, S., Tinti, A. & Fini, G. Spectroscopic Behavior of Copper Complexes of 
Nonsteroidal Anti-Inflammatory Drugs. Biopolymers 74, 120–124 (2004). 
34. Lay, P. & Hambley, T. Prophylaxis or treatment of cardiovascular inflammation. (2007). 
<https://encrypted.google.com/patents/WO2007110755A1?cl=ko> Accessed: 13/03/2018. 
35. Bakhtiar, R. & Ochiai, E. I. Pharmacological applications of inorganic complexes. Gen. 
Pharmacol. 32, 525–540 (1999). 
36. Kansara, S. G., Pandit, R. D. & Bhawe, V. G. Synthesis of some new Ibuprofen derivatives 
containing chief heterocyclic moiety like s-Triazine and evaluated for their analgesic activity. 
Rasayan J. Chem. 2, 699–705 (2009). 
37. Li, Y.-R. et al. Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as 
potential antibacterial and anti-inflammatory agents. Bioorg. Med. Chem. Lett. 25, 5052–5057 
(2015). 
38. Zawidlak-Wegrzynska, B. et al. Synthesis and antiproliferative properties of ibuprofen-oligo(3-
hydroxybutyrate)  conjugates. Eur. J. Med. Chem. 45, 1833–1842 (2010). 
39. Amir, M. & Kumar, S. Synthesis and evaluation of anti-inflammatory, analgesic, ulcerogenic 
and lipid peroxidation properties of ibuprofen derivatives. Acta Pharm. 57, 31–45 (2007). 
40. Reddy, L. V. et al. Design and synthesis of 1-aroyl-2-ylidene hydrazines under conventional 
and microwave irradiation conditions and their cytotoxic activities. J. Braz. Chem. Soc. 21, 
98–104 (2010). 
41. Kumar, P. & Narasimhan, B. Hydrazides/ Hydrazones as Antimicrobial and Anticancer 
Agents in the New Millennium. Mini-Reviews Med. Chem. 13, 971–987 (2013). 
42. Poggi, M. et al. New Isoniazid Complexes, Promising Agents Against Mycobacterium 
tuberculosis. J. Mex. Chem. Soc. 57, 198–204 (2013). 
43. West, E. D. & Dally, P. J. Effects of Iproniazid in Depressive Syndromes. Br. Med. J. 1, 1491–
1494 (1959). 
44. Finch, R. A., Shyam, K., Penketh, P. G. & Sartorelli, A. C. 1,2-Bis(methylsulfonyl)-1-(2-
chloroethyl)-2-(methylamino)carbonylhydrazine (101M): A Novel Sulfonylhydrazine Prodrug 
with Broad-Spectrum Antineoplastic Activity. Cancer Res. 61, 3033–3038 (2001). 
45. Pearson, R. G. Hard and Soft Acids and Bases. J. Am. Chem. Soc. 85, 3533–3539 (1963). 
46. Adamo, C. & Barone, V. Toward reliable density functional methods without adjustable 
parameters: The PBE0 model. J. Chem. Phys. 110, 6158–6170 (1999). 
47. Eichkorn, K., Weigend, F., Treutler, O. & Ahlrichs, R. Auxiliary basis sets for main row atoms 
and transition metals and their use to approximate Coulomb potentials. Theor. Chem. Acc. 
97, 119–124 (1997). 
55 
 
 
 
48. Neese, F. The ORCA program system. Wiley Interdiscip. Rev. Comput. Mol. Sci. 2, 73–78 
(2012). 
49. Izsák, R. & Neese, F. An overlap fitted chain of spheres exchange method. J. Chem. Phys. 
135, 144105 (2011). 
50. CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Third 
Informational Supplement (CLSI Document M100-S23). Clinical and Laboratory Standards 
Institute 33, (2013). 
51. Nunes, J. H. B. et al. Synthesis, characterization and in vitro biological assays of a silver(I) 
complex with 5-fluorouracil: a strategy to overcome multidrug resistant tumor cells. J. Fluor. 
Chem. 195, 93–101 (2017). 
52. Bachiega, P. et al. Antioxidant and antiproliferative activities in different maturation stages of 
broccoli (Brassica oleracea Italica) biofortified with selenium. Food Chem. 190, 771–776 
(2016). 
53. de Almeida, M. S. et al. Synthesis, DNA Binding, and Antiproliferative Activity of Novel 
Acridine-Thiosemicarbazone Derivatives. Int. J. Mol. Sci. 16, 13023–13042 (2015). 
54. Marchetti, G. M. et al. The anticancer activity of dichloromethane crude extract obtained from 
Calea pinnatifida. J. Exp. Pharmacol. 4, 157–162 (2012). 
55. Monks, A. et al. Feasibility of a High-Flux Anticancer Drug Screen Using a Diverse Panel of 
Cultured Human Tumor Cell Lines. JNCI J. Natl. Cancer Inst. 83, 757–766 (1991). 
56. Nakka, M. et al. Naproxen and ibuprofen based acyl hydrazone derivatives: Synthesis, 
structure analysis and cytotoxicity studies. J. Chem. Pharm. Res. 2, 393–409 (2010). 
57. Carvalho, M. a et al. Synthesis, spectroscopic characterization, DFT studies, and initial 
antibacterial assays in vitro of a new palladium(II) complex with tryptophan. J. Coord. Chem. 
65, 1700–1711 (2012). 
58. Carvalho, M. A. et al. Chemical and spectroscopic characterizations, ESI-QTOF mass 
spectrometric measurements and DFT studies of new complexes of palladium(II) with 
tryptamine and mefenamic acid. J. Mol. Struct. 1100, 6–13 (2015). 
59. Spera, M. B. M. et al. Palladium(II) complex with S-allyl-l-cysteine: New solid-state NMR 
spectroscopic measurements, molecular modeling and antibacterial assays. Spectrochim. 
Acta - Part A Mol. Biomol. Spectrosc. 78, 313–318 (2011). 
60. Abbehausen, C. et al. Synthesis, spectroscopic characterization, DFT studies, and 
antibacterial and antitumor activities of a novel water soluble Pd(II) complex with l-alliin. J. 
Mol. Struct. 1035, 421–426 (2013). 
61. Sousa, L. M. et al. Spectroscopic characterization and molecular modeling of novel 
palladium(II) complexes with carbazates and hydrazides. J. Mol. Struct. 1097, 15–22 (2015). 
62. Carvalho, M. A. et al. A new platinum complex with tryptophan: Synthesis, structural 
characterization, DFT studies and biological assays in vitro over human tumorigenic cells. 
56 
 
 
 
Spectrochim. Acta - Part A Mol. Biomol. Spectrosc. 122, 209–215 (2014). 
63. Rodrigues, M. A. et al. Platinum(II) complexes with carbazates and hydrazides: Synthesis, 
spectral characterization, computational modeling, and biological studies. Polyhedron 98, 
146–153 (2015). 
64. Drozdzewski, P., Brozyna, A., Kubiak, M. & Lis, T. Synthesis, structure and vibrational 
spectroscopy of palladium (II) complexes with 2-thiophenecarboxylic hydrazide (tch): Crystal 
structure of [PdCl2(tch)2]. 2dmf. Vib. Spectrosc. 40, 118–126 (2006). 
65. Nakamoto, K. Infrared and Raman Spectra of Inorganic and Coordination Compounds - Part 
B: Application in Coordination, Organometallic and Bioinorganic Chemistry. (John Wiley & 
Sons, 2009). 
66. Silverstein, M. R., Webster, F. X. & Kiemle, D. J. Spectrometric Identification of Organic 
Compounds. (John Wiley & Sons, 2005). doi:10.1016/0022-2860(76)87024-X 
67. Alvarez-Larena, A., Piniella, J. F., Borrell, J. I. & Beti, C. Crystal structure of dichloro(1,6-
diaminotetrahydropyrrolo[2,3-b]pyrrole-2,5(1H,4H)-dione)platinum(II),Pt(C6H10N4O2)Cl2. 
Zeitschrift für Kristallographie - Crystalline Materials 209, 293 (1994). 
68. Tacar, O., Sriamornsak, P. & Dass, C. R. Doxorubicin: An update on anticancer molecular 
action, toxicity and novel drug delivery systems. J. Pharm. Pharmacol. 65, 157–170 (2013). 
69. Muller, P. Y. & Milton, M. N. The determination and interpretation of the therapeutic index in 
drug development. Nat. Rev. Drug Discov. 11, 751–761 (2012). 
70. Sakhare, S. S., Rao, G. G., Mandape, S. N. & Pratap, S. Transcriptome profile of OVCAR3 
cisplatin-resistant ovarian cancer cell line. BMC Bioinformatics 15, P21 (2014). 
71. Hamilton, T. C. et al. Characterization of a Human Ovarian Carcinoma Cell Line 
(NIH:OVCAR-3) with Androgen and Estrogen Receptors. Cancer Res. 43, 5379–5389 (1983). 
72. Krishnamoorthy, P. et al. Copper(I) and nickel(II) complexes with 1:1 vs. 1:2 coordination of 
ferrocenyl hydrazone ligands: Do the geometry and composition of complexes affect DNA 
binding/cleavage, protein binding, antioxidant and cytotoxic activities? Dalt. Trans. 41, 4423–
4436 (2012). 
73. Zanvettor, N. T. et al. Inorganica Chimica Acta Copper (II), palladium (II) and platinum (II) 
complexes with 2,2-thiophen-yl-imidazole: Synthesis, spectroscopic characterization, X-ray 
crystallographic studies and interactions with calf-thymus DNA. Inorg. Chim. Acta 443, 304–
315 (2016). 
74. Tan, C., Liu, J., Chen, L., Shi, S. & Ji, L. Synthesis, structural characteristics, DNA binding 
properties and cytotoxicity studies of a series of Ru(III) complexes. J. Inorg. Biochem. 102, 
1644–1653 (2008). 
75. Shahabadi, N., Mohammadi, S. & Alizadeh, R. DNA interaction studies of a new platinum(II) 
complex containing different aromatic dinitrogen ligands. Bioinorg. Chem. Appl. 2011, 1–8 
(2011). 
57 
 
 
 
76. Shahabadi, N. & Mohammadi, S. Synthesis characterization and DNA interaction studies of a 
new Zn(II) complex containing different dinitrogen aromatic ligands. Bioinorg. Chem. Appl. 
2012, 1–8 (2012). 
77. Ljubijankić, N., Zahirović, A., Turkušić, E. & Kahrović, E. DNA Binding Properties of Two 
Ruthenium(III) Complexes Containing Schiff Bases Derived from Salicylaldehyde: 
Spectroscopic and Electrochemical Evidence of CT DNA Intercalation. Croat. Chem. Acta 86, 
215–222 (2013). 
78. Jung, Y. & Lippard, S. J. Direct cellular responses to platinum-induced DNA damage. Chem. 
Rev. 107, 1387–1407 (2007). 
79. Sirajuddin, M., Ali, S. & Badshah, A. Drug-DNA interactions and their study by UV-Visible , 
fluorescence spectroscopies and cyclic voltametry. J. Photochem. Photobiol. B Biol. 124, 1–
19 (2013). 
80. Kyros, L. et al. Synthesis, characterization, and binding properties towards CT-DNA and 
lipoxygenase of mixed-ligand silver(I) complexes with 2-mercaptothiazole and its derivatives 
and triphenylphosphine. J. Biol. Inorg. Chem. 19, 449–464 (2014). 
81. Zaki, M., Arjmand, F. & Tabassum, S. Current and future potential of metallo drugs: 
Revisiting DNA-binding of metal containing molecules and their diverse mechanism of action. 
Inorganica Chim. Acta 444, 1–22 (2016). 
82. Kypr, J., Kejnovská, I., Renčiuk, D. & Vorlíčková, M. Circular dichroism and conformational 
polymorphism of DNA. Nucleic Acids Res. 37, 1713–1725 (2009). 
83. Chang, Y.-M., Chen, C. K.-M. & Hou, M.-H. Conformational changes in DNA upon ligand 
binding monitored by circular dichroism. Int. J. Mol. Sci. 13, 3394–413 (2012). 
84. Dragan, A. I. et al. SYBR Green I: Fluorescence properties and interaction with DNA. J. 
Fluoresc. 22, 1189–1199 (2012). 
85. Zipper, H., Brunner, H., Bernhagen, J. & Vitzthum, F. Investigations on DNA intercalation and 
surface binding by SYBR Green I, its structure determination and methodological 
implications. Nucleic Acids Res. 32, 1–10 (2004). 
86. Loganathan, R. et al. Mixed ligand copper(II) complexes of N,N-bis(benzimidazol-2-
ylmethyl)amine (BBA)  with diimine co-ligands: efficient chemical nuclease and protease 
activities and cytotoxicity. Inorg. Chem. 51, 5512–5532 (2012). 
87. Zabost, E., Nowicka, A. M., Donten, M. & Stojek, Z. Substantial difference between 
temperature dependencies of dsDNA predenaturation process obtained by voltammetry and 
spectroscopy. Phys. Chem. Chem. Phys. 11, 8933–8938 (2009). 
88. Manzano, C. M. et al. Pt(II) and Pd(II) complexes with ibuprofen hydrazide: Characterization, 
theoretical calculations, antibacterial and antitumor assays and studies of interaction with CT-
DNA. J. Mol. Struct. 1154, 469–479 (2018). 
 
58 
 
 
 
  
7. Appendix 
 
Table S1 – Crystallographic experimental details. 
Chemical formula PdC26H40N4O2Cl2 
M.W. (gmol-1) 617.92 
Crystal system Monoclinic 
Space group P21/c 
Temperature (K) 150 
a, b, c (Å) 27.8148 (5), 8.9319 (3), 11.5187 (3) 
𝛽 (°) 92.462 (2) 
V (Å3) 2859.05 (13) 
Z 4 
Radiation type [Mo] Kα 
µ (mm-1) 0.87 
Crystal size (mm) 0.27 × 0.11 × 0.05 
Diffractometer Bruker APEX-II CCD 
 
 
Absorption correction 
Multi-scan, CrysAlis PRO 1.171.38.41 (Rigaku 
Oxford Diffraction, 2015) Empirical absorption 
correction using spherical harmonics, 
implemented in SCALE3 ABSPACK scaling 
algorithm. 
Tmin, Tmax 0.974, 1.000 
Number of measured, independent and 
observed [I > 2σ(I)] reflections 
43664, 5855, 5262 
Rint 0.037 
(sin θ/λ)max (Å−1) 0.625 
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R[F2 > 2σ(F2)],wR(F2), S 0.043, 0.103, 1.05 
Number of reflections 5855 
Number of parameters 361 
Number of restraints 72 
H-atom treatment H-atoms parameters constrained, 
w = 1/[σ2(Fo2) + (0.0417P)2 + 10.0059P] 
where P = (Fo2 + 2Fc2)/3 
Δρmax, Δρmin (e Å−3) 1.92, −1.19 
 
Table S2 - Bond lengths of [PdCl2(HIB)2] and a similar Pd(II) complex reported in the 
literature. 
Atoms Bond length (Å) [PdCl2(HIB)2]  Bond length (Å) literature* 
Pd-Cl1/Pd-Cl2 2.309(1)/2.2889(9) 2.303 
Pd-N1B/Pd-N1A 2.048(3)/2.036(3) 2.052 
N1A-N2A/N1B-N2B 1.425(4)/1.408(4) 1.431(5) 
C1B-O1B/C1A-O1A 1.226(5)/1.224(4) 1.236(5) 
* P. Drozdzewski, A. Brozyna, M. Kubiak, T. Lis, Vib. Spectrosc. 40 (2006) 118–126. 
Table S3 - Angles and torsions of [PdCl2(HIB)2] and a similar Pd(II) complex reported in the 
literature. 
Atoms Angles/torsions (°) [PdCl2(HIB)2] Angles/torsions (°) 
literature* 
Cl2-Pd-Cl1 177.41(4) 180.0 
N1B-Pd-N1A 178.6(1) 180.0 
N2A-N1A-Pd/N2B-N1B-Pd 113.1(2)/112.6(2) 114.6/114.6 
O1B-C1B-N2B/O1A-C1A-N2A 121.5(4)/121.4(3) 122.7(4)/122.7(4) 
C1B-N2B-N1B/C1A-N2A-N1A 118.9(3)/116.8(3) 116.6(3)/116.6(3) 
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C1B-N2B-N1B-Pd/ 
C1A-N2A-N1A-Pd 
119.6(3)/ -109.8(3) 114.2/114.2 
N2B-N1B-Pd-Cl1/ 
N2A-N1A-Pd-Cl2 
68.7(2)/ -69.0(2) 63.9/-63.9 
N2B-N1B-Pd-Cl2/ 
N2A-N1A-Pd-Cl1 
-113.5(2)/ 108.8(2) 116.1/-116.1 
* P. Drozdzewski, A. Brozyna, M. Kubiak, T. Lis, Vib. Spectrosc. 40 (2006) 118–126. 
Table S4 - Bond lengths for the HIB molecules in PdHIB crystal and those found for 188 
ibuprofen/ibuprofenate entries on CSD. 
Atoms Mean bond lengths (Å) found on 
CSD 
Bond lengths (Å) for HIB in 
PdHIB crystal* 
C3-C4 1.383(2) 1.390(6)/1.384(6) 
C4-C5 1.387(2) 1.392(6)/1.386(6) 
C5-C8 1.387(2) 1.370(6)/1.379(7) 
C7-C8 1.385(2) 1.368(6)/1.377(6) 
C6-C7 1.382(2) 1.356(7)/1.395(6) 
C8-C9 1.514(3) 1.52(2) [1.533(7)]/ 1.514(7) 
C3-C6 1.384(2) 1.383(6)/ 1.385(6) 
C2-C3 1.519(3) 1.525(6)/ 1.514(5) 
C1-C2 1.521(2) 1.539(6)/ 1.525(5) 
C2-C13 1.520(3) 1.507(7)/ 1.540(5) 
C1-O1 1.257(5) 1.226(5)/ 1.224(4) 
C9-C10 1.513(4) 1.61(2) [1.562(9)]/ 1.536(8) 
C10-C12 1.507(7) 1.43(3) [1.47(1)]/ 1.527(9) 
C10-C11 1.510(5) 1.49(3) [1.50(1)]/ 1.47(1) 
*the values in braces corresponds to the bond lengths of the disordered groups with lower level of 
occupation. 
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Table S5 - Angles for the HIB molecules and those found for 188 ibuprofen/ibuprofenate entries on 
CSD. 
Atoms Mean angles (°) found on 
CSD 
Angles (°) for HIB in PdHIB 
crystal* 
C3-C4-C5 120.7(1) 120.2(4) 
C4-C5-C8 121.4(2) 121.6(4) 
C4-C3-C6 117.9(1) 118.1(4) 
C2-C3-C4 120.7(3) 122.1(4) 
C5-C8-C7 117.4(2) 117.8(4) 
C5-C8-C9 121.2(2) 121.5(4) 
C7-C8-C9 121.4(2) 120.6(4) 
C6-C7-C8 121.3(1) 121.2(4) 
C8-C9-C10 114.2(2) 113.9(5) 
C3-C6-C7 121.2(1) 121.0(4) 
C6-C3-C2 121.3(4) 119.7(3) 
C1-C2-C3 109.1(2) 111.4(3) 
C3-C2-C13 112.7(3) 114.4(3) 
C1-C2-C13 110.7(3) 106.5(3) 
C2-C1-O1 118.2(5) 124.8(3) 
C9-C10-C11 111.7(6) 110.0(5) 
C9-C10-C12 111.2(5) 113.0(5) 
C11-C10-C12 111.2(4) 110.5(6) 
*the values in braces corresponds to the angles of the disordered groups with lower level of occupation. 
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Table S6 – Atomic coordinates of the DFT optimized structure of [PdCl2(HIB)2]  
  x y Z 
Pd 14.52299513997010 1.37780269510770 5.42146123680676 
Cl 13.58700985026270 3.22129131213484 6.44007809022994 
Cl 15.38331341831400 -0.52270205274187 4.43120658277483 
O 18.38839241763340 3.43847816817575 5.33086034534251 
O 11.85831170130270 1.49940416676350 2.33392296710987 
N 16.34606416439610 1.95543289462689 6.17315080716588 
N 17.46388433897110 1.39522937595500 5.52921300423203 
H 17.20300490735910 0.56343160841211 5.00183205708294 
N 12.75381770851890 0.74728053633405 4.63043371526504 
N 11.65294617208750 1.61877835378209 4.56968631343219 
H 11.68537302227820 2.31922619464788 5.30691272302085 
C 18.35235326227820 2.27638910513652 4.97832864176385 
C 19.18273289312290 1.66690707892809 3.86584559550423 
H 19.26306207685060 0.59215673097152 4.06364162705525 
C 18.39513256481490 1.83788851916112 2.57670716554661 
C 17.76418228240560 3.04053757675336 2.27097792390243 
H 17.82981461798690 3.87309457614410 2.96258383077229 
C 17.03116139046790 3.17484460099108 1.10384350391240 
H 16.52767769140420 4.11382135236590 0.89927406691102 
C 16.91272793398240 2.12746109674582 0.19514932460988 
C 17.54973138453270 0.92854690065727 0.50512943276649 
H 17.45584113674870 0.08432081869979 -0.17125040107784 
C 18.27073543740940 0.78232670400354 1.68053247976408 
H 18.72905402448400 -0.17395776985284 1.91270569165288 
C 16.13459664309820 2.28772984631669 -1.07936958158324 
H 15.30533592390490 2.98500323958929 -0.91397059842636 
H 15.68308087067490 1.32670185125970 -1.34644949309396 
C 16.96549887504530 2.78818135302530 -2.27157258043458 
H 17.83759752733240 2.12759074481315 -2.36082638275633 
C 17.46218237963780 4.21187726620302 -2.06866418810818 
H 16.61733093038870 4.90583048062966 -2.00427117885674 
H 18.08460887963480 4.52905738451912 -2.90884512454634 
H 18.05484371181790 4.31422311241406 -1.15771505757945 
C 16.16114310010820 2.69198681887508 -3.56040502021242 
H 15.82052771290520 1.67061956011550 -3.75198721987143 
H 16.75831324033310 3.02071454513652 -4.41527499523208 
H 15.27511322366250 3.33248379718539 -3.51131326723044 
C 20.58538311854050 2.25337277342144 3.78625514785279 
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H 21.13480826867330 2.07502950508510 4.71366029550486 
H 20.55067810112270 3.32791993629459 3.60310205940243 
H 21.13144340904040 1.78167110778063 2.96827265221161 
C 11.35194933863710 2.04116233307680 3.29383114273015 
C 10.36380629581830 3.19089277066389 3.23150193405179 
H 9.83597447116218 3.22045065732185 4.18976535938265 
C 9.34304852353077 2.95445397857367 2.14599206072969 
C 8.00509420605484 2.76772666254291 2.47013846259352 
H 7.69274018695443 2.82347481293851 3.50904958008916 
C 7.06381703931754 2.49215583808762 1.48904838499548 
H 6.02780998817731 2.33462604505441 1.77379722295109 
C 7.43519096069395 2.37862233878013 0.15331609703198 
C 8.77481946286324 2.58599688333401 -0.16673941751178 
H 9.09370987880931 2.49562492396982 -1.20028225716155 
C 9.71407265434786 2.87695903826289 0.80637284740310 
H 10.75212738782710 3.00363934001168 0.52570903245276 
C 6.43439891818333 2.03008237192677 -0.90891355404156 
H 5.67939975207412 1.36181618911503 -0.48250966417891 
H 6.93856555015005 1.46365569621161 -1.70088209429541 
C 5.71444826615956 3.21934060393624 -1.56349566218427 
H 5.17543821512659 3.76151722158942 -0.77546629915427 
C 6.68214525071831 4.18777113236809 -2.22680787259016 
H 6.14156030682569 5.00223431515357 -2.71553717707338 
H 7.27229362908563 3.67479515971463 -2.99441943632569 
H 7.37702107791951 4.62710012331142 -1.50837472584784 
C 4.69851938022977 2.69695132120105 -2.57043514209352 
H 4.15560565701612 3.51304563975722 -3.05453102372979 
H 3.96780057122875 2.03841911424211 -2.09277233371450 
H 5.20253227759982 2.12232101509094 -3.35467201561531 
C 11.13233408334060 4.50807892710105 3.07090975919179 
H 10.42741883565970 5.34089139444716 3.09496977148540 
H 11.66780238194050 4.53605767214049 2.12139619254721 
H 11.85798470707840 4.64474173027949 3.87653853258707 
H 16.37462556629780 1.72796631540731 7.16423967162922 
H 16.45012068961280 2.97321083226826 6.09797534675064 
H 12.47768995745760 -0.10538349625381 5.10991960707147 
H 12.94707507859620 0.49951623180669 3.65033547725660 
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Table S7 - Atomic coordinates of the DFT optimized structure of [PtCl2(HIB)2]   
  x y z 
Pt 13.09671553565640 3.71628718190179 -0.11631684120704 
Cl 12.64505876499310 5.88350921384581 0.52611561615750 
Cl 13.48127388333970 1.52091553555151 -0.72928269122925 
O 16.83907419162850 3.86450827788677 2.27720533492105 
O 8.80794731323724 3.72796285878035 -1.72942605635114 
N 15.05899473986270 4.08127357257898 0.36454784818861 
N 15.93141238340050 2.97785177674945 0.42870088161498 
H 15.53271688365740 2.14147260563934 0.01185303772234 
N 11.15419862451150 3.34012777058258 -0.63157182365186 
N 10.13209730986730 4.00393294636457 0.07085796822730 
H 10.48931583821530 4.71928988519033 0.69354293051021 
C 16.74579558808140 2.91550038479710 1.52287033485985 
C 17.49570889787930 1.60814549835795 1.68509611843019 
H 17.02332695433410 0.86759163411883 1.03136241533359 
C 18.94688747483380 1.71625296641657 1.25918829629873 
C 19.76032940664740 2.78031500329312 1.63496087198465 
H 19.33453668655900 3.60580482747958 2.19465658372045 
C 21.10646304791190 2.79486339889276 1.29484526967990 
H 21.71565158046370 3.64308653086425 1.59108268715141 
C 21.68796591142570 1.74751999763711 0.58338485335478 
C 20.86454615055020 0.68852698345741 0.21007389172033 
H 21.28348472502620 -0.13385250284476 -0.36123285983905 
C 19.51791689449170 0.67430385521030 0.53446674424945 
H 18.90062490751220 -0.15944756902967 0.21408086931420 
C 23.14352727651940 1.73736836276878 0.20789420254400 
H 23.48845356821120 2.76225738552943 0.02588858946637 
H 23.25060329312580 1.19949567179406 -0.73926620822043 
C 24.07675933954430 1.08036004238150 1.23800594067152 
H 23.61913146608360 0.12824781648022 1.53561097679498 
C 24.24650230907500 1.93365750052983 2.48667168795688 
H 24.75666764844990 2.87111194490832 2.24074851679165 
H 24.85121464269160 1.41423200837585 3.23427514086902 
H 23.28827534986690 2.18495688790916 2.94728452471359 
C 25.43158713836170 0.78287488230488 0.60566445961601 
H 25.33769703735220 0.11449785620332 -0.25387768322517 
H 26.10643947450140 0.31078889820836 1.32410561372803 
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H 25.90746259498410 1.70541579689168 0.25666741120799 
C 17.38691434592500 1.12667231968517 3.13354238594096 
H 16.34982216294230 0.91853951457613 3.40708228972470 
H 17.77848345612410 1.88550628926777 3.81143487668953 
H 17.97123531255590 0.21433453812758 3.26212810707801 
C 8.96429664791337 4.20087630414510 -0.62242132962981 
C 7.89751033110001 4.97207272408247 0.12640185086732 
H 8.38546445276825 5.55816432474432 0.91141438143061 
C 6.96372422280934 3.98892154358894 0.80844817313138 
C 6.86701770338694 3.96590395386924 2.19614452652004 
H 7.46628236432318 4.65272637088366 2.78596974835865 
C 6.02055145331713 3.07721686187234 2.83836713613786 
H 5.97532859459218 3.08088279905940 3.92305835786751 
C 5.23515298811506 2.18070773843726 2.11687224108023 
C 5.33876474411878 2.20594134634409 0.72871619062702 
H 4.74738120068232 1.51135235444284 0.14016199105343 
C 6.18723935313785 3.09138212793181 0.08049763434635 
H 6.25804007097326 3.06683147066461 -1.00133282845714 
C 4.30800148545929 1.23333672418644 2.82627043616053 
H 4.86367235532967 0.71542867510188 3.61656809463893 
H 3.96530743169651 0.45978770560511 2.13041769462300 
C 3.08316948008489 1.91151524578389 3.45576105952914 
H 3.44990536218447 2.74828335703245 4.06336472107727 
C 2.14135703316970 2.46862298490905 2.39830281959026 
H 1.31864771973710 3.01930402059074 2.86147591438449 
H 1.70550212793817 1.65721368051403 1.80502991896316 
H 2.65943665837987 3.14363398004705 1.71351624461852 
C 2.35068804219605 0.94522914454125 4.37379205422691 
H 1.51712047525702 1.44222829539532 4.87734093187020 
H 3.01379338459153 0.53587054672476 5.14049014645280 
H 1.94227645263344 0.10508463931629 3.80272606328383 
C 7.17507209013731 5.91679082760972 -0.82791466414699 
H 6.42249660961804 6.48653259975376 -0.28016725179266 
H 6.68218904858558 5.35578502081845 -1.62142415103566 
H 7.87502675852734 6.61467755032890 -1.29334074413410 
H 15.12169893491180 4.54282152430825 1.28018922045544 
H 15.42456756082400 4.75140221339290 -0.30999203545572 
H 11.03241512602460 2.33423991054505 -0.50947052626966 
H 10.99881162507320 3.52109108376459 -1.62830713388203 
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Table S8 - Bond lengths for the HIB molecules of the [PdCl2(HIB)2] crystal structure, the 
DFT optimized structures and those found for 188 ibuprofen/ibuprofenate entries on CSD. 
Atoms Mean bond 
lengths (Å) found 
on CSD (ibu/ibu-) 
Bond lengths (Å) 
for HIB 
[PdCl2(HIB)2]  
crystal structure * 
Bond lengths (Å) for 
HIB [PdCl2(HIB)2]  
DFT optimized 
structure 
Bond lengths (Å) for 
HIB [PtCl2(HIB)2]  DFT 
optimized structure 
C3-C4 1.383(2) 1.390(6)/1.384(6) 1.3921/1.3922 1.3913/1.3917 
C4-C5 1.387(2) 1.392(6)/1.386(6) 1.3848/1.3834 1.3852/1.3852 
C5-C8 1.387(2) 1.370(6)/1.379(7) 1.3917/1.3929 1.3932/1.3924 
C7-C8 1.385(2) 1.368(6)/1.377(6) 1.3926/1.3910 1.3922/1.3933 
C6-C7 1.382(2) 1.356(7)/1.395(6) 1.3867/1.3873 1.3871/1.3885 
C8-C9 1.514(3) 1.52(2) [1.533(7)]/ 
1.514(7) 
1.5019/1.5005 1.5035/1.5032 
C3-C6 1.384(2) 1.383(6)/ 1.385(6) 1.3903/1.3893 1.3923/1.3911 
C2-C3 1.519(3) 1.525(6)/ 1.514(5) 1.5203/1.5087 1.5178/1.5162 
C1-C2 1.521(2) 1.539(6)/ 1.525(5) 1.5161/1.5173 1.5144/1.5159 
C2-C13 1.520(3) 1.507(7)/ 1.540(5) 1.5224/1.5334 1.5248/1.5302 
C1-O1 1.257(5) 1.226(5)/ 1.224(4) 1.2149/1.2130 1.2139/1.2159 
C9-C10 1.513(4) 1.61(2) [1.562(9)]/ 
1.536(8) 
1.5369/1.5366 1.5351/1.5374 
C10-C12 1.507(7) 1.43(3) [1.47(1)]/ 
1.527(9) 
1.5214/1.5213 1.5209/1.5244 
C10-C11 1.510(5) 1.49(3) [1.50(1)]/ 
1.47(1) 
1.5223/1.5228 1.5217/1.5219 
C1-N2 - 1.338(5)/1.355(4) 1.3672/1.3772 1.3723/1.3654 
N2-N1 - 1.408(4)/1.425(4) 1.4064/1.4054 1.4067/1.4081 
*the values in braces corresponds to the bond lengths of the disordered groups with lower level of occupation. 
  
67 
 
 
 
 
Figure S1.  Crystal packing of the complex PdHIB obtained by single crystal X-ray 
diffraction. The views along axes a, b and c are shown. 
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Figure S2. Antiproliferative profile of the positive control doxorubicin. 
 
 
Figure S3. Antiproliferative profile of HIB. 
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Figure S4. Antiproliferative profile of [PdCl2(HIB)2]. 
 
 
Figure S5. Antiproliferative profile of [PtCl2(HIB)2]. 
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Figure S6. Antiproliferative profile of K2PdCl4. 
 
Figure S7. Antiproliferative profile of K2PdCl4. 
 
